<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin-top:.1pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:1.95pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:45.8pt;
	text-indent:-18.05pt;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.TableParagraph, li.TableParagraph, div.TableParagraph
	{mso-style-name:"Table Paragraph";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:5.35pt;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
.MsoChpDefault
	{font-family:"Calibri",sans-serif;}
.MsoPapDefault
	{text-autospace:none;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 11.0in;
	margin:69.0pt 61.0pt 14.0pt 61.0pt;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:8.5in 11.0in;
	margin:69.0pt 61.0pt 14.0pt 61.0pt;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:8.5in 11.0in;
	margin:69.0pt 61.0pt 14.0pt 61.0pt;}
div.WordSection3
	{page:WordSection3;}
@page WordSection4
	{size:8.5in 11.0in;
	margin:69.0pt 61.0pt 14.0pt 61.0pt;}
div.WordSection4
	{page:WordSection4;}
@page WordSection5
	{size:8.5in 11.0in;
	margin:69.0pt 61.0pt 14.0pt 61.0pt;}
div.WordSection5
	{page:WordSection5;}
@page WordSection6
	{size:8.5in 11.0in;
	margin:69.0pt 61.0pt 14.0pt 61.0pt;}
div.WordSection6
	{page:WordSection6;}
@page WordSection7
	{size:8.5in 11.0in;
	margin:69.0pt 61.0pt 14.0pt 61.0pt;}
div.WordSection7
	{page:WordSection7;}
@page WordSection8
	{size:8.5in 11.0in;
	margin:69.0pt 61.0pt 14.0pt 61.0pt;}
div.WordSection8
	{page:WordSection8;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoBodyText style='margin-top:1.65pt;margin-right:23.75pt;margin-bottom:
0in;margin-left:9.8pt;margin-bottom:.0001pt;line-height:115%'>This report may
include approved and non-approved uses, formulations, or treatment regimens.
The<span style='letter-spacing:.05pt'> </span>results reported may not reflect
the overall profile of a product. Before prescribing any product<span
style='letter-spacing:.05pt'> </span>mentioned in this report, healthcare
professionals should consult local prescribing information for the<span
style='letter-spacing:-2.35pt'> </span>product approved<span style='letter-spacing:
-.15pt'> </span>in<span style='letter-spacing:-.05pt'> </span>their<span
style='letter-spacing:-.1pt'> </span>country.</p>

<p class=MsoBodyText style='margin-top:.2pt'><span style='font-size:8.0pt'>&nbsp;</span></p>

<p class=MsoBodyText style='margin-top:0in;margin-right:16.45pt;margin-bottom:
0in;margin-left:9.75pt;margin-bottom:.0001pt;line-height:115%'>SPONSOR is
committed to publicly disclosing all medical research results that are
significant to patients,<span style='letter-spacing:-2.35pt'> </span>health
care providers or payers-whether favorable or unfavorable to the SPONSOR
product-in an<span style='letter-spacing:.05pt'> </span>accurate, objective and
balanced manner in order for our customers to make more informed decisions<span
style='letter-spacing:.05pt'> </span>about<span style='letter-spacing:-.15pt'> </span>our
products.</p>

<p class=MsoBodyText style='margin-top:0in;margin-right:12.65pt;margin-bottom:
0in;margin-left:9.75pt;margin-bottom:.0001pt;line-height:115%'>Personally
identifiable information (PII) within this document is either removed or
redacted (i.e., specific<span style='letter-spacing:-2.4pt'> </span>content is
masked irreversibly from view with a black bar) to protect personal privacy.
Personally<span style='letter-spacing:.05pt'> </span>identifiable<span
style='letter-spacing:-.05pt'> </span>information<span style='letter-spacing:
-.05pt'> </span>includes:</p>

<p class=MsoListParagraph style='margin-top:9.7pt;text-indent:-18.1pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>All<span style='letter-spacing:-.1pt'> </span>named<span
style='letter-spacing:-.1pt'> </span>persons<span style='letter-spacing:-.15pt'>
</span>associated<span style='letter-spacing:-.1pt'> </span>with<span
style='letter-spacing:-.2pt'> </span>the study</p>

<p class=MsoListParagraph><span style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>Patient<span
style='letter-spacing:-.2pt'> </span>identifiers<span style='letter-spacing:
-.1pt'> </span>within<span style='letter-spacing:-.15pt'> </span>text,<span
style='letter-spacing:-.05pt'> </span>tables,<span style='letter-spacing:-.2pt'>
</span>or<span style='letter-spacing:-.1pt'> </span>figures</p>

<p class=MsoListParagraph style='margin-top:2.1pt'><span style='font-family:
Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>By-patient<span style='letter-spacing:-.2pt'> </span>data<span
style='letter-spacing:-.1pt'> </span>listings</p>

<p class=MsoBodyText style='margin-top:.3pt'><span style='font-size:14.0pt'>&nbsp;</span></p>

<p class=MsoBodyText style='margin-top:0in;margin-right:22.05pt;margin-bottom:
0in;margin-left:9.8pt;margin-bottom:.0001pt;line-height:115%'>Anonymized
patient data may be made available subject to an approved research proposal
submitted.<span style='letter-spacing:-2.35pt'> </span>Information<span
style='letter-spacing:-.25pt'> </span>which<span style='letter-spacing:-.1pt'> </span>is<span
style='letter-spacing:-.15pt'> </span>considered<span style='letter-spacing:
-.1pt'> </span>intellectual<span style='letter-spacing:-.05pt'> </span>property<span
style='letter-spacing:-.15pt'> </span>or<span style='letter-spacing:-.05pt'> </span>company<span
style='letter-spacing:-.1pt'> </span>confidential<span style='letter-spacing:
-.05pt'> </span>was<span style='letter-spacing:-.1pt'> </span>also<span
style='letter-spacing:-.1pt'> </span>redacted.</p>

</div>

<span style='font-size:11.0pt;line-height:115%;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection2>

<p class=MsoBodyText style='margin-top:.2pt'><span style='position:absolute;
z-index:-1660206080;margin-left:947px;margin-top:778px;width:124px;height:26px'><img
width=83 height=17 src="1_files/image001.gif"></span></p>

<p class=MsoNormal align=center style='margin-top:4.4pt;margin-right:184.6pt;
margin-bottom:0in;margin-left:184.6pt;margin-bottom:.0001pt;text-align:center'><b><span
style='font-size:14.0pt'>STUDY<span style='letter-spacing:-.65pt'> </span>SYNOPSIS</span></b></p>

<p class=MsoNormal style='margin-top:.5pt'><b><span style='font-size:10.0pt'>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.85pt;border-collapse:collapse;border:none'>
 <tr style='height:32.05pt'>
  <td width=200 valign=top style='width:150.1pt;border:solid black 1.0pt;
  border-bottom:none;padding:0in 0in 0in 0in;height:32.05pt'>
  <p class=TableParagraph style='margin-top:3.0pt'><b><span style='font-size:
  10.0pt'>Name<span style='letter-spacing:-.3pt'> </span>of<span
  style='letter-spacing:-.15pt'> </span>sponsor/company:</span></b></p>
  <p class=TableParagraph style='margin-top:5.85pt;line-height:10.7pt'><span
  style='font-size:10.0pt'>Shire</span></p>
  </td>
  <td width=245 valign=top style='width:183.95pt;border-top:solid black 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:32.05pt'>
  <p class=TableParagraph style='margin-top:2.9pt;margin-right:4.3pt;
  margin-bottom:0in;margin-left:5.4pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>Individual Study Table Referring to Part of<span
  style='letter-spacing:-2.4pt'> </span>the<span style='letter-spacing:-.05pt'>
  </span>Dossier</span></p>
  </td>
  <td width=193 colspan=2 valign=top style='width:144.85pt;border-top:solid black 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:32.05pt'>
  <p class=TableParagraph style='margin-top:2.9pt;margin-right:26.55pt;
  margin-bottom:0in;margin-left:5.4pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>(for National Authority Use<span style='letter-spacing:
  -2.35pt'> </span>only)</span></p>
  </td>
 </tr>
 <tr style='height:2.95pt'>
  <td width=200 valign=top style='width:150.1pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:2.95pt'>
  <p class=TableParagraph style='margin:0in;margin-bottom:.0001pt'><span
  style='font-size:1.0pt'>&nbsp;</span></p>
  </td>
  <td width=245 rowspan=2 valign=top style='width:183.95pt;border:none;
  border-right:solid black 1.0pt;padding:0in 0in 0in 0in;height:2.95pt'>
  <p class=TableParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:5.4pt;margin-bottom:.0001pt;line-height:11.3pt'><span
  style='font-size:10.0pt'>Volume:</span></p>
  </td>
  <td width=193 colspan=2 rowspan=2 valign=top style='width:144.85pt;
  border:none;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:2.95pt'>
  <p class=TableParagraph style='margin:0in;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:14.35pt'>
  <td width=200 valign=top style='width:150.1pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:14.35pt'>
  <p class=TableParagraph style='margin-top:2.95pt;line-height:10.4pt'><b><span
  style='font-size:10.0pt'>Name<span style='letter-spacing:-.1pt'> </span>of<span
  style='letter-spacing:-.1pt'> </span>finished<span style='letter-spacing:
  -.05pt'> </span>product:</span></b></p>
  </td>
 </tr>
 <tr style='height:20.65pt'>
  <td width=200 valign=top style='width:150.1pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:20.65pt'>
  <p class=TableParagraph style='margin-top:5.95pt'><span style='font-size:
  10.0pt'>Firazyr<sup>®</sup></span></p>
  </td>
  <td width=245 valign=top style='width:183.95pt;border:none;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:20.65pt'>
  <p class=TableParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:5.4pt;margin-bottom:.0001pt;line-height:11.0pt'><span
  style='font-size:10.0pt'>Page:</span></p>
  </td>
  <td width=193 colspan=2 valign=top style='width:144.85pt;border:none;
  border-right:solid black 1.0pt;padding:0in 0in 0in 0in;height:20.65pt'>
  <p class=TableParagraph style='margin:0in;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:17.6pt'>
  <td width=200 valign=top style='width:150.1pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:17.6pt'>
  <p class=TableParagraph style='margin-top:2.95pt'><b><span style='font-size:
  10.0pt'>Name<span style='letter-spacing:-.15pt'> </span>of<span
  style='letter-spacing:-.15pt'> </span>active<span style='letter-spacing:-.05pt'>
  </span>ingredient:</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.95pt;border:none;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:17.6pt'>
  <p class=TableParagraph style='margin:0in;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=193 colspan=2 valign=top style='width:144.85pt;border:none;
  border-right:solid black 1.0pt;padding:0in 0in 0in 0in;height:17.6pt'>
  <p class=TableParagraph style='margin:0in;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:17.35pt'>
  <td width=200 valign=top style='width:150.1pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:17.35pt'>
  <p class=TableParagraph style='margin-top:2.75pt'><span style='font-size:
  10.0pt'>icatibant</span></p>
  </td>
  <td width=245 valign=top style='width:183.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:17.35pt'>
  <p class=TableParagraph style='margin:0in;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=193 colspan=2 valign=top style='width:144.85pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:17.35pt'>
  <p class=TableParagraph style='margin:0in;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:29.0pt'>
  <td width=639 colspan=4 valign=top style='width:478.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:29.0pt'>
  <p class=TableParagraph style='margin-top:2.9pt;margin-right:36.6pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><b><span
  style='font-size:10.0pt'>Title of the study: </span></b><span
  style='font-size:10.0pt'>An Open-Label Study of Icatibant in Japanese
  Subjects with Acute Attacks of Hereditary<span style='letter-spacing:-2.35pt'>
  </span>Angioedema</span></p>
  </td>
 </tr>
 <tr style='height:29.3pt'>
  <td width=574 colspan=3 valign=top style='width:430.3pt;border-top:none;
  border-left:solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:
  none;padding:0in 0in 0in 0in;height:29.3pt'>
  <p class=TableParagraph style='margin-top:2.8pt;margin-right:31.0pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><b><span
  style='font-size:10.0pt'>Investigator(s): </span></b><span style='font-size:
  10.0pt'>A total of 8 investigators participated in the study. The principal
  investigator was<span style='letter-spacing:-2.4pt'> </span>MD,<span
  style='letter-spacing:-.05pt'> </span>PhD.</span></p>
  </td>
  <td width=65 valign=top style='width:48.6pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:29.3pt'>
  <p class=TableParagraph align=right style='margin-top:2.8pt;margin-right:
  13.2pt;margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:
  right'><span style='font-size:10.0pt'>,</span></p>
  </td>
 </tr>
 <tr style='height:18.4pt'>
  <td width=639 colspan=4 valign=top style='width:478.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:18.4pt'>
  <p class=TableParagraph style='margin-top:2.8pt'><b><span style='font-size:
  10.0pt'>Study<span style='letter-spacing:-.15pt'> </span>center(s):<span
  style='letter-spacing:-.2pt'> </span></span></b><span style='font-size:10.0pt'>Subjects<span
  style='letter-spacing:-.2pt'> </span>were<span style='letter-spacing:-.15pt'>
  </span>screened<span style='letter-spacing:-.15pt'> </span>at<span
  style='letter-spacing:-.2pt'> </span>8<span style='letter-spacing:-.15pt'> </span>sites<span
  style='letter-spacing:-.15pt'> </span>in<span style='letter-spacing:-.15pt'> </span>Japan.</span></p>
  </td>
 </tr>
 <tr style='height:19.7pt'>
  <td width=639 colspan=4 valign=top style='width:478.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:19.7pt'>
  <p class=TableParagraph style='margin-top:2.8pt'><b><span style='font-size:
  10.0pt'>Publications<span style='letter-spacing:-.15pt'> </span>(references):<span
  style='letter-spacing:-.2pt'> </span></span></b><span style='font-size:10.0pt'>Not<span
  style='letter-spacing:-.1pt'> </span>applicable</span></p>
  </td>
 </tr>
 <tr style='height:52.45pt'>
  <td width=445 colspan=2 valign=top style='width:334.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:52.45pt'>
  <p class=TableParagraph style='margin-top:2.95pt'><b><span style='font-size:
  10.0pt'>Study<span style='letter-spacing:-.1pt'> </span>period:</span></b></p>
  <p class=TableParagraph style='margin-top:5.9pt'><span style='font-size:10.0pt'>Date<span
  style='letter-spacing:-.1pt'> </span>of<span style='letter-spacing:-.2pt'> </span>first<span
  style='letter-spacing:-.1pt'> </span>subject<span style='letter-spacing:-.1pt'>
  </span>consent:<span style='letter-spacing:-.1pt'> </span>18<span
  style='letter-spacing:-.1pt'> </span>Mar<span style='letter-spacing:-.2pt'> </span>2015</span></p>
  <p class=TableParagraph><span style='font-size:10.0pt'>Date<span
  style='letter-spacing:-.15pt'> </span>of<span style='letter-spacing:-.1pt'> </span>last<span
  style='letter-spacing:-.1pt'> </span>subject<span style='letter-spacing:-.2pt'>
  </span>follow-up<span style='letter-spacing:-.15pt'> </span>visit:<span
  style='letter-spacing:-.1pt'> </span>12<span style='letter-spacing:-.05pt'> </span>Feb<span
  style='letter-spacing:-.15pt'> </span>2016</span></p>
  </td>
  <td width=193 colspan=2 valign=top style='width:144.85pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:52.45pt'>
  <p class=TableParagraph style='margin-top:2.8pt;margin-right:0in;margin-bottom:
  0in;margin-left:5.4pt;margin-bottom:.0001pt'><b><span style='font-size:10.0pt'>Phase<span
  style='letter-spacing:-.1pt'> </span>of<span style='letter-spacing:-.05pt'> </span>development:<span
  style='letter-spacing:-.05pt'> </span></span></b><span style='font-size:10.0pt'>3</span></p>
  </td>
 </tr>
 <tr style='height:29.0pt'>
  <td width=639 colspan=4 valign=top style='width:478.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:29.0pt'>
  <p class=TableParagraph style='margin-top:2.9pt;margin-right:11.7pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><b><span
  style='font-size:10.0pt'>Objectives: </span></b><span style='font-size:10.0pt'>To
  evaluate the efficacy, pharmacokinetics, and safety of icatibant for the
  treatment of acute attacks in<span style='letter-spacing:-2.35pt'> </span>Japanese<span
  style='letter-spacing:-.05pt'> </span>subjects with type<span
  style='letter-spacing:-.15pt'> </span>I<span style='letter-spacing:-.05pt'> </span>or<span
  style='letter-spacing:-.05pt'> </span>type II<span style='letter-spacing:
  -.1pt'> </span>hereditary<span style='letter-spacing:-.05pt'> </span>angioedema
  (HAE).</span></p>
  </td>
 </tr>
 <tr style='height:308.95pt'>
  <td width=639 colspan=4 valign=top style='width:478.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:308.95pt'>
  <p class=TableParagraph style='margin-top:2.95pt'><b><span style='font-size:
  10.0pt'>Methodology:</span></b></p>
  <p class=TableParagraph style='margin-top:5.9pt;margin-right:8.0pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>This Phase 3 study was an uncontrolled, open-label,
  single-arm study to evaluate the efficacy and safety of icatibant<span
  style='letter-spacing:-2.35pt'> </span>as a treatment for acute attacks of
  HAE in Japanese subjects. In addition, the study evaluated the
  pharmacokinetic<span style='letter-spacing:.05pt'> </span>(PK) properties of
  icatibant in Japanese subjects with HAE. It was conducted as a multicenter
  study with sites in<span style='letter-spacing:.05pt'> </span>Japan.<span
  style='letter-spacing:-.1pt'> </span>The<span style='letter-spacing:-.15pt'> </span>study<span
  style='letter-spacing:-.1pt'> </span>enrolled<span style='letter-spacing:
  -.05pt'> </span>male<span style='letter-spacing:-.05pt'> </span>and<span
  style='letter-spacing:-.15pt'> </span>female<span style='letter-spacing:-.05pt'>
  </span>Japanese<span style='letter-spacing:-.1pt'> </span>subjects<span
  style='letter-spacing:-.05pt'> </span>with<span style='letter-spacing:-.1pt'>
  </span>HAE<span style='letter-spacing:-.2pt'> </span>who<span
  style='letter-spacing:-.1pt'> </span>were<span style='letter-spacing:-.15pt'>
  </span>18<span style='letter-spacing:-.05pt'> </span>years<span
  style='letter-spacing:-.15pt'> </span>of<span style='letter-spacing:-.1pt'> </span>age<span
  style='letter-spacing:-.1pt'> </span>and<span style='letter-spacing:-.1pt'> </span>older.</span></p>
  <p class=TableParagraph style='margin-right:13.0pt'><span style='font-size:
  10.0pt'>Subjects may have been screened at any time before enrollment.
  Following informed consent and completion of<span style='letter-spacing:.05pt'>
  </span>screening procedures, subjects entered into a waiting period until the
  onset of an HAE attack. An adequate number<span style='letter-spacing:-2.35pt'>
  </span>of subjects were screened to provide eligible subjects with a
  confirmed diagnosis of HAE who presented with an<span style='letter-spacing:
  .05pt'> </span>acute non-laryngeal or laryngeal attack within 6 hours of the
  symptoms of the attack becoming moderate to severe<span style='letter-spacing:
  -2.35pt'> </span>(abdominal and/or cutaneous attacks) or mild to moderate
  (laryngeal attacks), but not more than 12 hours from the<span
  style='letter-spacing:-2.35pt'> </span>onset of the<span style='letter-spacing:
  -.05pt'> </span>attack.</span></p>
  <p class=TableParagraph style='margin-top:5.95pt;margin-right:.1in;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>Enrollment and treatment occurred only when subjects
  presented with cutaneous and/or abdominal symptoms which<span
  style='letter-spacing:-2.4pt'> </span>were judged to be at least moderate or
  with laryngeal symptoms that were judged to be at least mild within the<span
  style='letter-spacing:.05pt'> </span>protocol-specified time frame. The
  location and severity of the attack at baseline was determined by the
  investigator<span style='letter-spacing:-2.35pt'> </span>global<span
  style='letter-spacing:-.05pt'> </span>assessment.</span></p>
  <p class=TableParagraph style='margin-top:6.05pt;margin-right:8.05pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>Enrolled subjects received treatment with icatibant
  for 1 acute non-laryngeal or laryngeal attack. It was planned that<span
  style='letter-spacing:-2.4pt'> </span>treatment would consist of 1
  subcutaneous (SC) injection of icatibant at a dose of 30 mg; however, a
  maximum of 3<span style='letter-spacing:-2.35pt'> </span>SC injections of
  icatibant that were at least 6 hours apart could have been given for
  treatment of an attack if, within<span style='letter-spacing:.05pt'> </span>48
  hours of the initial treatment, there was insufficient relief or worsening of
  symptoms. If symptoms worsened or<span style='letter-spacing:.05pt'> </span>recurred
  more than 48 hours after the initial treatment, the event was considered as a
  new attack. A new attack was<span style='letter-spacing:.05pt'> </span>not<span
  style='letter-spacing:-.1pt'> </span>treated<span style='letter-spacing:-.1pt'>
  </span>with icatibant,<span style='letter-spacing:-.1pt'> </span>but<span
  style='letter-spacing:-.15pt'> </span>rather,<span style='letter-spacing:
  -.05pt'> </span>was<span style='letter-spacing:-.1pt'> </span>managed<span
  style='letter-spacing:-.05pt'> </span>according to<span style='letter-spacing:
  -.1pt'> </span>the<span style='letter-spacing:-.05pt'> </span>current<span
  style='letter-spacing:-.1pt'> </span>HAE<span style='letter-spacing:-.05pt'> </span>standard<span
  style='letter-spacing:-.1pt'> </span>of<span style='letter-spacing:-.05pt'> </span>care<span
  style='letter-spacing:-.1pt'> </span>in<span style='letter-spacing:-.1pt'> </span>Japan.</span></p>
  <p class=TableParagraph><span style='font-size:10.0pt'>Doses<span
  style='letter-spacing:-.25pt'> </span>were<span style='letter-spacing:-.25pt'>
  </span>administered<span style='letter-spacing:-.25pt'> </span>by<span
  style='letter-spacing:-.2pt'> </span>a<span style='letter-spacing:-.2pt'> </span>healthcare<span
  style='letter-spacing:-.2pt'> </span>professional<span style='letter-spacing:
  -.2pt'> </span>(HCP)<span style='letter-spacing:-.2pt'> </span>or<span
  style='letter-spacing:-.25pt'> </span>self-administered<span
  style='letter-spacing:-.2pt'> </span>by<span style='letter-spacing:-.25pt'> </span>the<span
  style='letter-spacing:-.2pt'> </span>subject<span style='letter-spacing:-.2pt'>
  </span>at<span style='letter-spacing:-.2pt'> </span>the<span
  style='letter-spacing:-.25pt'> </span>hospital/clinic</span></p>
  <p class=TableParagraph style='margin-top:0in;line-height:11.5pt'><span
  style='font-size:10.0pt'>under the supervision of an HCP. Subjects were
  encouraged to self-administer icatibant under supervision and<span
  style='letter-spacing:-2.35pt'> </span>received<span style='letter-spacing:
  -.1pt'> </span>training<span style='letter-spacing:-.1pt'> </span>on<span
  style='letter-spacing:-.1pt'> </span>the<span style='letter-spacing:-.1pt'> </span>appropriate<span
  style='letter-spacing:-.1pt'> </span>self-injection<span style='letter-spacing:
  -.1pt'> </span>technique<span style='letter-spacing:-.05pt'> </span>from<span
  style='letter-spacing:-.2pt'> </span>an<span style='letter-spacing:-.1pt'> </span>HCP<span
  style='letter-spacing:-.1pt'> </span>prior<span style='letter-spacing:-.1pt'>
  </span>to<span style='letter-spacing:-.1pt'> </span>treatment.<span
  style='letter-spacing:-.05pt'> </span>This<span style='letter-spacing:-.1pt'>
  </span>training<span style='letter-spacing:-.1pt'> </span>was</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=153 style='border:none'></td>
  <td width=150 style='border:none'></td>
  <td width=88 style='border:none'></td>
  <td width=52 style='border:none'></td>
 </tr>
</table>

</div>

<span style='font-size:10.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection3>

<p class=MsoNormal style='margin-top:.1pt'><span style='position:absolute;
z-index:-1660205568;margin-left:296px;margin-top:1707px;width:86px;height:26px'><img
width=57 height=17 src="1_files/image002.gif"></span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.85pt;border-collapse:collapse;border:none'>
 <tr style='height:32.05pt'>
  <td width=200 valign=top style='width:150.1pt;border:solid black 1.0pt;
  border-bottom:none;padding:0in 0in 0in 0in;height:32.05pt'>
  <p class=TableParagraph style='margin-top:2.95pt'><b><span style='font-size:
  10.0pt'>Name<span style='letter-spacing:-.3pt'> </span>of<span
  style='letter-spacing:-.15pt'> </span>sponsor/company:</span></b></p>
  <p class=TableParagraph style='margin-top:5.9pt;line-height:10.7pt'><span
  style='font-size:10.0pt'>Shire</span></p>
  </td>
  <td width=245 valign=top style='width:183.95pt;border-top:solid black 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:32.05pt'>
  <p class=TableParagraph style='margin-top:2.8pt;margin-right:4.3pt;
  margin-bottom:0in;margin-left:5.4pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>Individual Study Table Referring to Part of<span
  style='letter-spacing:-2.4pt'> </span>the<span style='letter-spacing:-.05pt'>
  </span>Dossier</span></p>
  </td>
  <td width=193 valign=top style='width:144.85pt;border-top:solid black 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:32.05pt'>
  <p class=TableParagraph style='margin-top:2.8pt;margin-right:26.55pt;
  margin-bottom:0in;margin-left:5.4pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>(for National Authority Use<span style='letter-spacing:
  -2.35pt'> </span>only)</span></p>
  </td>
 </tr>
 <tr style='height:2.95pt'>
  <td width=200 valign=top style='width:150.1pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:2.95pt'>
  <p class=TableParagraph style='margin:0in;margin-bottom:.0001pt'><span
  style='font-size:1.0pt'>&nbsp;</span></p>
  </td>
  <td width=245 rowspan=2 valign=top style='width:183.95pt;border:none;
  border-right:solid black 1.0pt;padding:0in 0in 0in 0in;height:2.95pt'>
  <p class=TableParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:5.4pt;margin-bottom:.0001pt;line-height:11.3pt'><span
  style='font-size:10.0pt'>Volume:</span></p>
  </td>
  <td width=193 rowspan=2 valign=top style='width:144.85pt;border:none;
  border-right:solid black 1.0pt;padding:0in 0in 0in 0in;height:2.95pt'>
  <p class=TableParagraph style='margin:0in;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:14.3pt'>
  <td width=200 valign=top style='width:150.1pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:14.3pt'>
  <p class=TableParagraph style='margin-top:2.95pt;line-height:10.4pt'><b><span
  style='font-size:10.0pt'>Name<span style='letter-spacing:-.1pt'> </span>of<span
  style='letter-spacing:-.1pt'> </span>finished<span style='letter-spacing:
  -.05pt'> </span>product:</span></b></p>
  </td>
 </tr>
 <tr style='height:20.6pt'>
  <td width=200 valign=top style='width:150.1pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:20.6pt'>
  <p class=TableParagraph><span style='font-size:10.0pt'>Firazyr<sup>®</sup></span></p>
  </td>
  <td width=245 valign=top style='width:183.95pt;border:none;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:20.6pt'>
  <p class=TableParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:5.4pt;margin-bottom:.0001pt;line-height:10.95pt'><span
  style='font-size:10.0pt'>Page:</span></p>
  </td>
  <td width=193 valign=top style='width:144.85pt;border:none;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:20.6pt'>
  <p class=TableParagraph style='margin:0in;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:17.6pt'>
  <td width=200 valign=top style='width:150.1pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:17.6pt'>
  <p class=TableParagraph style='margin-top:3.0pt'><b><span style='font-size:
  10.0pt'>Name<span style='letter-spacing:-.15pt'> </span>of<span
  style='letter-spacing:-.15pt'> </span>active<span style='letter-spacing:-.05pt'>
  </span>ingredient:</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.95pt;border:none;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:17.6pt'>
  <p class=TableParagraph style='margin:0in;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=193 valign=top style='width:144.85pt;border:none;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:17.6pt'>
  <p class=TableParagraph style='margin:0in;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:17.35pt'>
  <td width=200 valign=top style='width:150.1pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:17.35pt'>
  <p class=TableParagraph style='margin-top:2.7pt'><span style='font-size:10.0pt'>icatibant</span></p>
  </td>
  <td width=245 valign=top style='width:183.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:17.35pt'>
  <p class=TableParagraph style='margin:0in;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=193 valign=top style='width:144.85pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:17.35pt'>
  <p class=TableParagraph style='margin:0in;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:106.95pt'>
  <td width=639 colspan=3 valign=top style='width:478.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:106.95pt'>
  <p class=TableParagraph style='margin-top:0in;line-height:11.35pt'><span
  style='font-size:10.0pt'>offered<span style='letter-spacing:-.1pt'> </span>either<span
  style='letter-spacing:-.15pt'> </span>at<span style='letter-spacing:-.1pt'> </span>the<span
  style='letter-spacing:-.15pt'> </span>hospital/clinic<span style='letter-spacing:
  -.15pt'> </span>or<span style='letter-spacing:-.15pt'> </span>in<span
  style='letter-spacing:-.1pt'> </span>the<span style='letter-spacing:-.15pt'> </span>subjects<span
  style='letter-spacing:-.1pt'> </span>home.</span></p>
  <p class=TableParagraph style='margin-right:5.45pt'><span style='font-size:
  10.0pt'>Subjects were hospitalized or remained in the clinic for a minimum of
  8 hours after treatment. Assessments of HAE<span style='letter-spacing:.05pt'>
  </span>symptoms were performed by the subject and investigator during the
  hospital/clinic stay. Safety and PK assessments<span style='letter-spacing:
  -2.35pt'> </span>were<span style='letter-spacing:-.1pt'> </span>also<span
  style='letter-spacing:-.05pt'> </span>conducted.<span style='letter-spacing:
  -.1pt'> </span>Subjects<span style='letter-spacing:-.1pt'> </span>were<span
  style='letter-spacing:-.05pt'> </span>discharged<span style='letter-spacing:
  -.1pt'> </span>when<span style='letter-spacing:-.1pt'> </span>deemed<span
  style='letter-spacing:-.05pt'> </span>clinically<span style='letter-spacing:
  -.05pt'> </span>stable by<span style='letter-spacing:-.1pt'> </span>the<span
  style='letter-spacing:-.05pt'> </span>investigator.</span></p>
  <p class=TableParagraph style='margin-right:5.35pt'><span style='font-size:
  10.0pt'>After discharge and through 5 days post-treatment, subjects recorded
  the results of self-assessments of HAE<span style='letter-spacing:.05pt'> </span>symptoms
  in a diary. After discharge and until Day 7 (+3 days) visit, subjects
  reported any adverse events (AEs) and<span style='letter-spacing:-2.35pt'> </span>use<span
  style='letter-spacing:.05pt'> </span>of<span style='letter-spacing:.05pt'> </span>concomitant<span
  style='letter-spacing:.1pt'> </span>medications.<span style='letter-spacing:
  .05pt'> </span>A<span style='letter-spacing:.1pt'> </span>contact<span
  style='letter-spacing:.1pt'> </span>via<span style='letter-spacing:.1pt'> </span>telephone<span
  style='letter-spacing:.1pt'> </span>was<span style='letter-spacing:.1pt'> </span>scheduled<span
  style='letter-spacing:.1pt'> </span>at<span style='letter-spacing:.05pt'> </span>48<span
  style='letter-spacing:.05pt'> </span>hours<span style='letter-spacing:.1pt'> </span>post-treatment.<span
  style='letter-spacing:.1pt'> </span>Subjects<span style='letter-spacing:.05pt'>
  </span>returned<span style='letter-spacing:-.05pt'> </span>to<span
  style='letter-spacing:-.05pt'> </span>the<span style='letter-spacing:-.15pt'>
  </span>hospital/clinic<span style='letter-spacing:-.05pt'> </span>for<span
  style='letter-spacing:-.1pt'> </span>safety<span style='letter-spacing:-.05pt'>
  </span>follow-up<span style='letter-spacing:-.1pt'> </span>at<span
  style='letter-spacing:-.05pt'> </span>the<span style='letter-spacing:-.1pt'> </span>final<span
  style='letter-spacing:-.05pt'> </span>visit<span style='letter-spacing:-.05pt'>
  </span>scheduled at<span style='letter-spacing:-.2pt'> </span>7<span
  style='letter-spacing:-.1pt'> </span>days<span style='letter-spacing:-.15pt'>
  </span>post-treatment.</span></p>
  </td>
 </tr>
 <tr style='height:35.0pt'>
  <td width=639 colspan=3 valign=top style='width:478.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:35.0pt'>
  <p class=TableParagraph style='margin-top:3.0pt'><b><span style='font-size:
  10.0pt'>Number<span style='letter-spacing:-.1pt'> </span>of subjects (planned
  and<span style='letter-spacing:-.05pt'> </span>analyzed):</span></b></p>
  <p class=TableParagraph style='margin-top:5.85pt'><span style='font-size:
  10.0pt'>A<span style='letter-spacing:-.1pt'> </span>total<span
  style='letter-spacing:-.15pt'> </span>of<span style='letter-spacing:-.15pt'> </span>8<span
  style='letter-spacing:-.1pt'> </span>subjects<span style='letter-spacing:
  -.1pt'> </span>were<span style='letter-spacing:-.15pt'> </span>planned<span
  style='letter-spacing:-.05pt'> </span>and<span style='letter-spacing:-.05pt'>
  </span>treated<span style='letter-spacing:-.1pt'> </span>in<span
  style='letter-spacing:-.1pt'> </span>this<span style='letter-spacing:-.05pt'>
  </span>study.</span></p>
  </td>
 </tr>
 <tr style='height:80.95pt'>
  <td width=639 colspan=3 valign=top style='width:478.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:80.95pt'>
  <p class=TableParagraph style='margin-top:2.95pt'><b><span style='font-size:
  10.0pt'>Diagnosis<span style='letter-spacing:-.3pt'> </span>and<span
  style='letter-spacing:-.2pt'> </span>main<span style='letter-spacing:-.2pt'> </span>criteria<span
  style='letter-spacing:-.25pt'> </span>for<span style='letter-spacing:-.25pt'>
  </span>inclusion:</span></b></p>
  <p class=TableParagraph style='margin-top:5.9pt;margin-right:8.3pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>Japanese subjects, 18 years of age or older, with
  HAE type I or II were enrolled in this study. Subjects who<span
  style='letter-spacing:.05pt'> </span>presented with a moderate to severe
  acute cutaneous and/or abdominal HAE attack, or a mild to moderate laryngeal<span
  style='letter-spacing:-2.35pt'> </span>HAE attack were eligible to receive
  study drug within 12 hours of attack onset. Subjects presenting with symptoms<span
  style='letter-spacing:.05pt'> </span>of severe laryngeal edema were excluded
  from participating in this study. Subjects who received previous treatment<span
  style='letter-spacing:-2.35pt'> </span>with icatibant<span style='letter-spacing:
  -.1pt'> </span>were<span style='letter-spacing:-.05pt'> </span>excluded<span
  style='letter-spacing:-.1pt'> </span>from<span style='letter-spacing:-.1pt'> </span>participating<span
  style='letter-spacing:.05pt'> </span>in<span style='letter-spacing:.05pt'> </span>this<span
  style='letter-spacing:-.05pt'> </span>study.</span></p>
  </td>
 </tr>
 <tr style='height:46.5pt'>
  <td width=639 colspan=3 valign=top style='width:478.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:46.5pt'>
  <p class=TableParagraph style='margin-top:3.0pt'><b><span style='font-size:
  10.0pt'>Investigational<span style='letter-spacing:-.15pt'> </span>product,<span
  style='letter-spacing:-.1pt'> </span>dose,<span style='letter-spacing:-.1pt'>
  </span>mode<span style='letter-spacing:-.1pt'> </span>of<span
  style='letter-spacing:-.15pt'> </span>administration,<span style='letter-spacing:
  -.1pt'> </span>and<span style='letter-spacing:-.15pt'> </span>batch<span
  style='letter-spacing:-.15pt'> </span>number(s):</span></b></p>
  <p class=TableParagraph style='margin-top:5.85pt;margin-right:9.55pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>Icatibant at a dose of 30 mg was administered as a
  single SC injection. The batch and/or lot number of product used<span
  style='letter-spacing:-2.35pt'> </span>in<span style='letter-spacing:-.05pt'>
  </span>this<span style='letter-spacing:-.05pt'> </span>study<span
  style='letter-spacing:-.15pt'> </span>was        .</span></p>
  </td>
 </tr>
 <tr style='height:34.95pt'>
  <td width=639 colspan=3 valign=top style='width:478.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:34.95pt'>
  <p class=TableParagraph style='margin-top:2.95pt'><b><span style='font-size:
  10.0pt'>Reference<span style='letter-spacing:-.2pt'> </span>product(s),<span
  style='letter-spacing:-.2pt'> </span>dose,<span style='letter-spacing:-.25pt'>
  </span>mode<span style='letter-spacing:-.2pt'> </span>of<span
  style='letter-spacing:-.25pt'> </span>administration,<span style='letter-spacing:
  -.25pt'> </span>and<span style='letter-spacing:-.2pt'> </span>batch<span
  style='letter-spacing:-.15pt'> </span>number(s):</span></b></p>
  <p class=TableParagraph style='margin-top:5.9pt'><span style='font-size:10.0pt'>Not<span
  style='letter-spacing:-.2pt'> </span>applicable.</span></p>
  </td>
 </tr>
 <tr style='height:46.5pt'>
  <td width=639 colspan=3 valign=top style='width:478.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:46.5pt'>
  <p class=TableParagraph style='margin-top:3.0pt'><b><span style='font-size:
  10.0pt'>Duration<span style='letter-spacing:-.15pt'> </span>of<span
  style='letter-spacing:-.15pt'> </span>treatment:</span></b></p>
  <p class=TableParagraph style='margin-top:5.85pt;margin-right:34.95pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>Efficacy and safety measures were recorded through 5
  days post-treatment, and a final safety assessment was<span style='letter-spacing:
  -2.4pt'> </span>scheduled<span style='letter-spacing:-.05pt'> </span>at<span
  style='letter-spacing:-.1pt'> </span>7<span style='letter-spacing:-.05pt'> </span>days<span
  style='letter-spacing:-.05pt'> </span>post-treatment.</span></p>
  </td>
 </tr>
 <tr style='height:174.3pt'>
  <td width=639 colspan=3 valign=top style='width:478.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:174.3pt'>
  <p class=TableParagraph style='margin-top:2.95pt'><b><span style='font-size:
  10.0pt'>Criteria<span style='letter-spacing:-.3pt'> </span>for<span
  style='letter-spacing:-.25pt'> </span>evaluation:</span></b></p>
  <p class=TableParagraph style='margin-top:5.9pt'><u><span style='font-size:
  10.0pt'>Efficacy<span style='letter-spacing:-.05pt'> </span>Endpoints</span></u></p>
  <p class=TableParagraph style='margin-top:5.95pt;margin-right:14.9pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>The primary endpoint of this study was the time to
  onset of symptom relief (TOSR) as assessed by the subject and<span
  style='letter-spacing:-2.35pt'> </span>defined as a 50% reduction from the
  pretreatment score in the 3-symptom composite visual analog scale (VAS)<span
  style='letter-spacing:.05pt'> </span>score<span style='letter-spacing:-.15pt'>
  </span>for<span style='letter-spacing:-.05pt'> </span>non-laryngeal<span
  style='letter-spacing:-.05pt'> </span>attacks<span style='letter-spacing:
  -.05pt'> </span>and<span style='letter-spacing:-.1pt'> </span>5-symptom<span
  style='letter-spacing:-.3pt'> </span>composite<span style='letter-spacing:
  -.05pt'> </span>VAS<span style='letter-spacing:-.1pt'> </span>score<span
  style='letter-spacing:-.05pt'> </span>for<span style='letter-spacing:-.05pt'>
  </span>laryngeal<span style='letter-spacing:-.05pt'> </span>attacks.</span></p>
  <p class=TableParagraph><span style='font-size:10.0pt'>The<span
  style='letter-spacing:-.15pt'> </span>secondary<span style='letter-spacing:
  -.2pt'> </span>endpoints<span style='letter-spacing:-.2pt'> </span>of<span
  style='letter-spacing:-.2pt'> </span>this<span style='letter-spacing:-.1pt'> </span>study<span
  style='letter-spacing:-.2pt'> </span>were:</span></p>
  <p class=TableParagraph style='margin-top:6.05pt;margin-right:0in;margin-bottom:
  0in;margin-left:23.35pt;margin-bottom:.0001pt;text-indent:-18.05pt'><span
  style='font-size:10.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span style='font-size:10.0pt'>Time<span style='letter-spacing:
  -.15pt'> </span>to<span style='letter-spacing:-.1pt'> </span>onset<span
  style='letter-spacing:-.2pt'> </span>of<span style='letter-spacing:-.15pt'> </span>symptom<span
  style='letter-spacing:-.2pt'> </span>relief<span style='letter-spacing:-.1pt'>
  </span>using<span style='letter-spacing:-.1pt'> </span>the<span
  style='letter-spacing:-.2pt'> </span>VAS<span style='letter-spacing:-.1pt'> </span>score<span
  style='letter-spacing:-.15pt'> </span>for<span style='letter-spacing:-.1pt'> </span>a<span
  style='letter-spacing:-.2pt'> </span>single<span style='letter-spacing:-.2pt'>
  </span>primary<span style='letter-spacing:-.1pt'> </span>symptom</span></p>
  <p class=TableParagraph style='margin-top:5.9pt;margin-right:45.05pt;
  margin-bottom:0in;margin-left:23.35pt;margin-bottom:.0001pt;text-indent:-.25in'><span
  style='font-size:10.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span style='font-size:10.0pt'>Change<span style='letter-spacing:
  -.15pt'> </span>from<span style='letter-spacing:-.15pt'> </span>pretreatment<span
  style='letter-spacing:-.1pt'> </span>in the<span style='letter-spacing:-.1pt'>
  </span>3-symptom<span style='letter-spacing:-.1pt'> </span>or<span
  style='letter-spacing:-.15pt'> </span>5-symptom<span style='letter-spacing:
  -.15pt'> </span>composite<span style='letter-spacing:-.05pt'> </span>VAS<span
  style='letter-spacing:-.05pt'> </span>scores<span style='letter-spacing:-.1pt'>
  </span>at<span style='letter-spacing:-.1pt'> </span>2,<span style='letter-spacing:
  -.15pt'> </span>4,<span style='letter-spacing:-.05pt'> </span>and<span
  style='letter-spacing:-.1pt'> </span>8<span style='letter-spacing:-.1pt'> </span>hours<span
  style='letter-spacing:-2.35pt'> </span>post-treatment</span></p>
  <p class=TableParagraph style='margin-left:23.35pt;text-indent:-18.05pt'><span
  style='font-size:10.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span style='font-size:10.0pt'>Symptom<span style='letter-spacing:
  -.3pt'> </span>severity<span style='letter-spacing:-.15pt'> </span>score<span
  style='letter-spacing:-.15pt'> </span>assessed<span style='letter-spacing:
  -.2pt'> </span>by<span style='letter-spacing:-.2pt'> </span>the<span
  style='letter-spacing:-.15pt'> </span>subject<span style='letter-spacing:
  -.15pt'> </span>and<span style='letter-spacing:-.15pt'> </span>the<span
  style='letter-spacing:-.2pt'> </span>investigator<span style='letter-spacing:
  -.2pt'> </span>for<span style='letter-spacing:-.15pt'> </span>individual<span
  style='letter-spacing:-.15pt'> </span>symptoms</span></p>
  <p class=TableParagraph style='margin-top:5.95pt;margin-right:0in;margin-bottom:
  0in;margin-left:23.35pt;margin-bottom:.0001pt;text-indent:-18.05pt;
  line-height:11.4pt'><span style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
  style='font-size:10.0pt'>Global<span style='letter-spacing:-.15pt'> </span>assessment<span
  style='letter-spacing:-.15pt'> </span>of<span style='letter-spacing:-.15pt'> </span>abdominal,<span
  style='letter-spacing:-.1pt'> </span>cutaneous,<span style='letter-spacing:
  -.1pt'> </span>and<span style='letter-spacing:-.1pt'> </span>laryngeal<span
  style='letter-spacing:-.15pt'> </span>symptoms<span style='letter-spacing:
  -.1pt'> </span>by<span style='letter-spacing:-.15pt'> </span>the<span
  style='letter-spacing:-.05pt'> </span>investigator<span style='letter-spacing:
  -.15pt'> </span>at<span style='letter-spacing:-.15pt'> </span>2,<span
  style='letter-spacing:-.15pt'> </span>4,</span></p>
  </td>
 </tr>
</table>

</div>

<span style='font-size:10.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection4>

<p class=MsoNormal style='margin-top:.1pt'><b><span style='font-size:2.5pt'>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.85pt;border-collapse:collapse;border:none'>
 <tr style='height:35.0pt'>
  <td width=200 valign=top style='width:150.1pt;border:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:35.0pt'>
  <p class=TableParagraph style='margin-top:2.95pt'><b><span style='font-size:
  10.0pt'>Name<span style='letter-spacing:-.3pt'> </span>of<span
  style='letter-spacing:-.15pt'> </span>sponsor/company:</span></b></p>
  <p class=TableParagraph style='margin-top:5.9pt'><span style='font-size:10.0pt'>Shire</span></p>
  </td>
  <td width=245 rowspan=3 valign=top style='width:183.95pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:35.0pt'>
  <p class=TableParagraph style='margin-top:2.8pt;margin-right:4.3pt;
  margin-bottom:0in;margin-left:5.4pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>Individual Study Table Referring to Part of<span
  style='letter-spacing:-2.4pt'> </span>the<span style='letter-spacing:-.05pt'>
  </span>Dossier</span></p>
  <p class=TableParagraph style='margin-top:6.05pt;margin-right:142.4pt;
  margin-bottom:0in;margin-left:5.4pt;margin-bottom:.0001pt;line-height:151%'><span
  style='font-size:10.0pt;line-height:151%;letter-spacing:-.05pt'>Volume:</span><span
  style='font-size:10.0pt;line-height:151%;letter-spacing:-2.35pt'> </span><span
  style='font-size:10.0pt;line-height:151%'>Page:</span></p>
  </td>
  <td width=193 rowspan=3 valign=top style='width:144.85pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:35.0pt'>
  <p class=TableParagraph style='margin-top:2.8pt;margin-right:26.55pt;
  margin-bottom:0in;margin-left:5.4pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>(for National Authority Use<span style='letter-spacing:
  -2.35pt'> </span>only)</span></p>
  </td>
 </tr>
 <tr style='height:34.95pt'>
  <td width=200 valign=top style='width:150.1pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:34.95pt'>
  <p class=TableParagraph style='margin-top:2.95pt'><b><span style='font-size:
  10.0pt'>Name<span style='letter-spacing:-.1pt'> </span>of<span
  style='letter-spacing:-.1pt'> </span>finished<span style='letter-spacing:
  -.05pt'> </span>product:</span></b></p>
  <p class=TableParagraph style='margin-top:5.9pt'><span style='font-size:10.0pt'>Firazyr<sup>®</sup></span></p>
  </td>
 </tr>
 <tr style='height:35.0pt'>
  <td width=200 valign=top style='width:150.1pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:35.0pt'>
  <p class=TableParagraph style='margin-top:3.0pt'><b><span style='font-size:
  10.0pt'>Name<span style='letter-spacing:-.15pt'> </span>of<span
  style='letter-spacing:-.15pt'> </span>active<span style='letter-spacing:-.05pt'>
  </span>ingredient:</span></b></p>
  <p class=TableParagraph style='margin-top:5.85pt'><span style='font-size:
  10.0pt'>icatibant</span></p>
  </td>
 </tr>
 <tr style='height:3.2in'>
  <td width=639 colspan=3 valign=top style='width:478.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:3.2in'>
  <p class=TableParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:23.35pt;margin-bottom:.0001pt;line-height:11.35pt'><span
  style='font-size:10.0pt'>and<span style='letter-spacing:-.15pt'> </span>8<span
  style='letter-spacing:-.15pt'> </span>hours<span style='letter-spacing:-.15pt'>
  </span>post-treatment</span></p>
  <p class=TableParagraph style='margin-left:23.35pt;text-indent:-18.05pt'><span
  style='font-size:10.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span style='font-size:10.0pt'>Time<span style='letter-spacing:
  -.15pt'> </span>to<span style='letter-spacing:-.1pt'> </span>initial<span
  style='letter-spacing:-.15pt'> </span>symptom<span style='letter-spacing:
  -.25pt'> </span>improvement<span style='letter-spacing:-.15pt'> </span>as<span
  style='letter-spacing:-.15pt'> </span>assessed<span style='letter-spacing:
  -.2pt'> </span>by<span style='letter-spacing:-.15pt'> </span>the<span
  style='letter-spacing:-.15pt'> </span>subject<span style='letter-spacing:
  -.15pt'> </span>and<span style='letter-spacing:-.1pt'> </span>the<span
  style='letter-spacing:-.15pt'> </span>investigator</span></p>
  <p class=TableParagraph style='margin-right:56.85pt;text-indent:0in;
  line-height:147%'><span style='font-size:10.0pt;line-height:147%;font-family:
  Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span style='font-size:10.0pt;line-height:147%'>Time to almost
  complete symptom relief, defined as a score &lt;10 mm on each individual VAS
  score<span style='letter-spacing:-2.35pt'> </span><u>Pharmacokinetic<span
  style='letter-spacing:-.05pt'> </span>Endpoints</u></span></p>
  <p class=TableParagraph style='margin-top:.55pt'><span style='font-size:10.0pt'>The
  sparse PK samples were taken from each subject at 0.75 and 2 hours post SC
  administration. The plasma<span style='letter-spacing:.05pt'> </span>concentrations<span
  style='letter-spacing:-.3pt'> </span>of<span style='letter-spacing:-.15pt'> </span>icatibant<span
  style='letter-spacing:-.15pt'> </span>and<span style='letter-spacing:-.15pt'>
  </span>its<span style='letter-spacing:-.2pt'> </span>2<span style='letter-spacing:
  -.15pt'> </span>metabolites<span style='letter-spacing:-.1pt'> </span>M1<span
  style='letter-spacing:-.15pt'> </span>and<span style='letter-spacing:-.25pt'>
  </span>M2<span style='letter-spacing:-.2pt'> </span>were<span
  style='letter-spacing:-.25pt'> </span>determined<span style='letter-spacing:
  -.1pt'> </span>by<span style='letter-spacing:-.2pt'> </span>validated<span
  style='letter-spacing:-.2pt'> </span>bioanalysis<span style='letter-spacing:
  -.15pt'> </span>method.</span></p>
  <p class=TableParagraph style='margin-right:17.1pt'><span style='font-size:
  10.0pt'>The icatibant plasma concentrations from this study were included in
  the population PK analysis along with those<span style='letter-spacing:-2.35pt'>
  </span>from previous studies in healthy subjects and non-Japanese subjects
  with HAE. The effect of covariates (ie, age,<span style='letter-spacing:.05pt'>
  </span>body weight, sex, race, disease state) on the PK of icatibant was
  evaluated and a population PK model was<span style='letter-spacing:.05pt'> </span>established.
  Icatibant PK parameters (ie, maximum observed plasma concentration [C<sub>max</sub>],
  area under the curve<span style='letter-spacing:.05pt'> </span>[AUC])<span
  style='letter-spacing:-.15pt'> </span>were<span style='letter-spacing:-.1pt'>
  </span>estimated<span style='letter-spacing:.05pt'> </span>by<span
  style='letter-spacing:-.1pt'> </span>a population PK<span style='letter-spacing:
  -.15pt'> </span>modeling<span style='letter-spacing:.05pt'> </span>approach.</span></p>
  <p class=TableParagraph style='margin-top:5.95pt'><u><span style='font-size:
  10.0pt'>Safety<span style='letter-spacing:-.15pt'> </span>Endpoints</span></u></p>
  <p class=TableParagraph style='margin-top:6.05pt;margin-right:6.35pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>The safety and tolerability of icatibant was
  evaluated through the assessment of AEs, including clinically relevant<span
  style='letter-spacing:.05pt'> </span>worsening of the signs and symptoms of a
  treated HAE attack, injection site reactions, clinical laboratory testing<span
  style='letter-spacing:.05pt'> </span>(hematology, serum chemistry,
  coagulation, and urinalysis), vital sign measurements, electrocardiogram
  (ECG), and<span style='letter-spacing:-2.35pt'> </span>physical<span
  style='letter-spacing:-.05pt'> </span>examination.</span></p>
  </td>
 </tr>
 <tr style='height:308.95pt'>
  <td width=639 colspan=3 valign=top style='width:478.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:308.95pt'>
  <p class=TableParagraph style='margin-top:2.95pt'><b><span style='font-size:
  10.0pt'>Statistical<span style='letter-spacing:-.05pt'> </span>methods:</span></b></p>
  <p class=TableParagraph style='margin-top:5.9pt;margin-right:12.6pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>The primary efficacy endpoint, TOSR, was the time
  from investigational product administration to onset of<span
  style='letter-spacing:.05pt'> </span>symptom relief, where onset of symptom
  relief was defined as the earliest of 3 consecutive non-missing<span
  style='letter-spacing:.05pt'> </span>measurements<span style='letter-spacing:
  -.1pt'> </span>for<span style='letter-spacing:-.1pt'> </span>which<span
  style='letter-spacing:-.1pt'> </span>there<span style='letter-spacing:-.1pt'>
  </span>is<span style='letter-spacing:-.1pt'> </span>at<span style='letter-spacing:
  -.05pt'> </span>least<span style='letter-spacing:-.1pt'> </span>a<span
  style='letter-spacing:-.1pt'> </span>50%<span style='letter-spacing:-.1pt'> </span>reduction<span
  style='letter-spacing:-.05pt'> </span>in<span style='letter-spacing:-.1pt'> </span>the<span
  style='letter-spacing:-.1pt'> </span>pretreatment<span style='letter-spacing:
  -.05pt'> </span>composite<span style='letter-spacing:-.15pt'> </span>VAS<span
  style='letter-spacing:-.05pt'> </span>score.<span style='letter-spacing:-.15pt'>
  </span>The<span style='letter-spacing:-.2pt'> </span>composite<span
  style='letter-spacing:-2.35pt'> </span>VAS score was defined as the average
  of individual VAS scores for 3 symptoms (skin swelling, skin pain, and<span
  style='letter-spacing:.05pt'> </span>abdominal pain) for non-laryngeal
  attacks and 5 symptoms (skin swelling, skin pain, abdominal pain, difficulty<span
  style='letter-spacing:.05pt'> </span>swallowing, and voice change) for
  laryngeal attacks. Time to onset of symptom relief was summarized using the<span
  style='letter-spacing:.05pt'> </span>Kaplan-Meier<span style='letter-spacing:
  -.15pt'> </span>method.</span></p>
  <p class=TableParagraph style='margin-top:5.95pt;margin-right:9.65pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>The key secondary efficacy endpoint was time to
  onset of primary symptom relief (TOSR-P), which was calculated<span
  style='letter-spacing:-2.35pt'> </span>from the time of icatibant
  administration to the onset of primary symptom relief. Onset of primary
  symptom relief<span style='letter-spacing:.05pt'> </span>was determined
  retrospectively as the earliest of 3 consecutive non-missing measurements in
  which there was a<span style='letter-spacing:.05pt'> </span>reduction less
  than Y=6/7 X  16 if X &#8805;30 or 68% if X &lt;30 mm in the pretreatment
  primary VAS score. Time to<span style='letter-spacing:.05pt'> </span>onset<span
  style='letter-spacing:-.1pt'> </span>of<span style='letter-spacing:-.05pt'> </span>primary<span
  style='letter-spacing:-.05pt'> </span>symptom<span style='letter-spacing:
  -.15pt'> </span>relief<span style='letter-spacing:-.05pt'> </span>was
  summarized<span style='letter-spacing:-.05pt'> </span>using the<span
  style='letter-spacing:-.15pt'> </span>Kaplan-Meier<span style='letter-spacing:
  -.15pt'> </span>method.</span></p>
  <p class=TableParagraph style='margin-right:24.9pt'><span style='font-size:
  10.0pt'>Other secondary endpoints (time to almost complete symptom relief
  [TACSR], time to initial symptom<span style='letter-spacing:.05pt'> </span>improvement
  [TISI], and time to onset of symptom relief for individual VAS symptoms) were
  also summarized<span style='letter-spacing:-2.35pt'> </span>using the
  Kaplan-Meier method. Other secondary efficacy endpoints, including change
  from baseline when<span style='letter-spacing:.05pt'> </span>appropriate,<span
  style='letter-spacing:-.05pt'> </span>were summarized<span style='letter-spacing:
  -.05pt'> </span>descriptively.</span></p>
  <p class=TableParagraph><span style='font-size:10.0pt'>Plasma samples were
  assayed for concentrations of icatibant and its 2 major metabolites (M1 and
  M2). Plasma<span style='letter-spacing:.05pt'> </span>concentrations of
  icatibant and its metabolites, and nominal sampling time are listed by
  subject and plasma<span style='letter-spacing:.05pt'> </span><span
  style='letter-spacing:-.1pt'>concentrations</span><span style='letter-spacing:
  -.55pt'> </span><span style='letter-spacing:-.1pt'>were</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.1pt'>summarized</span><span
  style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.1pt'>using</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.1pt'>descriptive</span><span
  style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>statistics</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>(ie,</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>mean,</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>standard</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>deviation</span><span
  style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.05pt'>[SD],</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>coefficient</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>of</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>variation</span><span
  style='letter-spacing:-2.35pt'> </span><span style='letter-spacing:-.05pt'>[CV%],
  median, minimum and maximum). Plasma concentrations below </span>the lower
  limit of quantification (LLOQ)<span style='letter-spacing:.05pt'> </span>were<span
  style='letter-spacing:-.55pt'> </span>treated<span style='letter-spacing:
  -.55pt'> </span>as<span style='letter-spacing:-.45pt'> </span>0<span
  style='letter-spacing:-.55pt'> </span>for<span style='letter-spacing:-.5pt'> </span>the<span
  style='letter-spacing:-.55pt'> </span>calculation<span style='letter-spacing:
  -.5pt'> </span>of<span style='letter-spacing:-.55pt'> </span>descriptive<span
  style='letter-spacing:-.5pt'> </span>statistics<span style='letter-spacing:
  -.5pt'> </span>for<span style='letter-spacing:-.45pt'> </span>plasma<span
  style='letter-spacing:-.55pt'> </span>concentrations<span style='letter-spacing:
  -.5pt'> </span>at<span style='letter-spacing:-.5pt'> </span>each<span
  style='letter-spacing:-.5pt'> </span>sampling<span style='letter-spacing:
  -.45pt'> </span>time.</span></p>
  <p class=TableParagraph style='margin-top:5.2pt;margin-right:9.85pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt;line-height:11.5pt'><span
  style='font-size:10.0pt'>The PK parameters of icatibant (ie, C<sub>max</sub>,
  AUC) were estimated based on a 2-compartment population PK modeling<span
  style='letter-spacing:-2.35pt'> </span>using<span style='letter-spacing:-.15pt'>
  </span>sparse<span style='letter-spacing:-.15pt'> </span>samples<span
  style='letter-spacing:-.15pt'> </span>collected<span style='letter-spacing:
  -.15pt'> </span>in<span style='letter-spacing:-.15pt'> </span>this<span
  style='letter-spacing:-.15pt'> </span>study.<span style='letter-spacing:-.25pt'>
  </span>The<span style='letter-spacing:-.15pt'> </span>effect<span
  style='letter-spacing:-.25pt'> </span>of<span style='letter-spacing:-.15pt'> </span>covariates<span
  style='letter-spacing:-.15pt'> </span>(ie,<span style='letter-spacing:-.15pt'>
  </span>age,<span style='letter-spacing:-.2pt'> </span>body<span
  style='letter-spacing:-.2pt'> </span>weight,<span style='letter-spacing:-.15pt'>
  </span>sex,<span style='letter-spacing:-.1pt'> </span>race,<span
  style='letter-spacing:-.2pt'> </span>disease<span style='letter-spacing:-.15pt'>
  </span>state)</span></p>
  </td>
 </tr>
</table>

</div>

<span style='font-size:10.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection5>

<p class=MsoNormal style='margin-top:.1pt'><b><span style='font-size:2.5pt'>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.85pt;border-collapse:collapse;border:none'>
 <tr style='height:35.0pt'>
  <td width=200 valign=top style='width:150.1pt;border:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:35.0pt'>
  <p class=TableParagraph style='margin-top:2.95pt'><b><span style='font-size:
  10.0pt'>Name<span style='letter-spacing:-.3pt'> </span>of<span
  style='letter-spacing:-.15pt'> </span>sponsor/company:</span></b></p>
  <p class=TableParagraph style='margin-top:5.9pt'><span style='font-size:10.0pt'>Shire</span></p>
  </td>
  <td width=245 rowspan=3 valign=top style='width:183.95pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:35.0pt'>
  <p class=TableParagraph style='margin-top:2.8pt;margin-right:4.3pt;
  margin-bottom:0in;margin-left:5.4pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>Individual Study Table Referring to Part of<span
  style='letter-spacing:-2.4pt'> </span>the<span style='letter-spacing:-.05pt'>
  </span>Dossier</span></p>
  <p class=TableParagraph style='margin-top:6.05pt;margin-right:142.4pt;
  margin-bottom:0in;margin-left:5.4pt;margin-bottom:.0001pt;line-height:151%'><span
  style='font-size:10.0pt;line-height:151%;letter-spacing:-.05pt'>Volume:</span><span
  style='font-size:10.0pt;line-height:151%;letter-spacing:-2.35pt'> </span><span
  style='font-size:10.0pt;line-height:151%'>Page:</span></p>
  </td>
  <td width=193 rowspan=3 valign=top style='width:144.85pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:35.0pt'>
  <p class=TableParagraph style='margin-top:2.8pt;margin-right:26.55pt;
  margin-bottom:0in;margin-left:5.4pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>(for National Authority Use<span style='letter-spacing:
  -2.35pt'> </span>only)</span></p>
  </td>
 </tr>
 <tr style='height:34.95pt'>
  <td width=200 valign=top style='width:150.1pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:34.95pt'>
  <p class=TableParagraph style='margin-top:2.95pt'><b><span style='font-size:
  10.0pt'>Name<span style='letter-spacing:-.1pt'> </span>of<span
  style='letter-spacing:-.1pt'> </span>finished<span style='letter-spacing:
  -.05pt'> </span>product:</span></b></p>
  <p class=TableParagraph style='margin-top:5.9pt'><span style='font-size:10.0pt'>Firazyr<sup>®</sup></span></p>
  </td>
 </tr>
 <tr style='height:35.0pt'>
  <td width=200 valign=top style='width:150.1pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:35.0pt'>
  <p class=TableParagraph style='margin-top:3.0pt'><b><span style='font-size:
  10.0pt'>Name<span style='letter-spacing:-.15pt'> </span>of<span
  style='letter-spacing:-.15pt'> </span>active<span style='letter-spacing:-.05pt'>
  </span>ingredient:</span></b></p>
  <p class=TableParagraph style='margin-top:5.85pt'><span style='font-size:
  10.0pt'>icatibant</span></p>
  </td>
 </tr>
 <tr style='height:153.45pt'>
  <td width=639 colspan=3 valign=top style='width:478.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:153.45pt'>
  <p class=TableParagraph style='margin-top:0in;line-height:11.35pt'><span
  style='font-size:10.0pt'>on<span style='letter-spacing:-.15pt'> </span>the<span
  style='letter-spacing:-.2pt'> </span>PK<span style='letter-spacing:-.1pt'> </span>of<span
  style='letter-spacing:-.05pt'> </span>icatibant<span style='letter-spacing:
  -.1pt'> </span>was<span style='letter-spacing:-.1pt'> </span>evaluated.</span></p>
  <p class=TableParagraph style='margin-right:10.45pt'><span style='font-size:
  10.0pt'>Adverse events were coded using the Medical Dictionary for Regulatory
  Activities (MedDRA), version 16.1.<span style='letter-spacing:.05pt'> </span><span
  style='letter-spacing:-.1pt'>Treatment-emergent</span><span style='letter-spacing:
  -.5pt'> </span><span style='letter-spacing:-.1pt'>adverse</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.1pt'>events</span><span
  style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.1pt'>(TEAEs)</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.1pt'>were</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.1pt'>summarized</span><span
  style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.05pt'>by</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>system</span><span
  style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>organ</span><span
  style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.05pt'>class</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>(SOC)</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>and</span><span
  style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.05pt'>preferred</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>term</span><span
  style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>(PT).</span>
  <span style='letter-spacing:-.05pt'>The number and percentage of subjects
  experiencing a TEAE, as well as </span>total number of TEAEs, were
  summarized.<span style='letter-spacing:-2.35pt'> </span>Treatment-emergent<span
  style='letter-spacing:-.55pt'> </span>AEs<span style='letter-spacing:-.5pt'> </span>by<span
  style='letter-spacing:-.5pt'> </span>SOC<span style='letter-spacing:-.5pt'> </span>and<span
  style='letter-spacing:-.5pt'> </span>PT<span style='letter-spacing:-.55pt'> </span>also<span
  style='letter-spacing:-.45pt'> </span>were<span style='letter-spacing:-.5pt'>
  </span>summarized<span style='letter-spacing:-.45pt'> </span>by<span
  style='letter-spacing:-.55pt'> </span>severity<span style='letter-spacing:
  -.55pt'> </span>and<span style='letter-spacing:-.5pt'> </span>by<span
  style='letter-spacing:-.55pt'> </span>relationship<span style='letter-spacing:
  -.45pt'> </span>to<span style='letter-spacing:-.45pt'> </span>treatment.</span></p>
  <p class=TableParagraph style='margin-top:6.05pt;margin-right:5.8pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>The number and percentage of subjects with any
  injection site reactions by type and any severe reactions by type are<span
  style='letter-spacing:-2.35pt'> </span>summarized. The number and percentage
  of subjects with injection site reactions are summarized by maximum<span
  style='letter-spacing:.05pt'> </span>severity<span style='letter-spacing:
  -.1pt'> </span>at<span style='letter-spacing:-.05pt'> </span>any<span
  style='letter-spacing:-.1pt'> </span>time point<span style='letter-spacing:
  -.05pt'> </span>and<span style='letter-spacing:-.1pt'> </span>for each<span
  style='letter-spacing:-.05pt'> </span>study<span style='letter-spacing:-.1pt'>
  </span>time point.</span></p>
  <p class=TableParagraph style='margin-top:5.9pt'><span style='font-size:10.0pt'>Local<span
  style='letter-spacing:-.2pt'> </span>tolerability<span style='letter-spacing:
  -.15pt'> </span>included<span style='letter-spacing:-.15pt'> </span>symptoms<span
  style='letter-spacing:-.15pt'> </span>at<span style='letter-spacing:-.15pt'> </span>the<span
  style='letter-spacing:-.2pt'> </span>injection<span style='letter-spacing:
  -.15pt'> </span>site<span style='letter-spacing:-.25pt'> </span>and<span
  style='letter-spacing:-.15pt'> </span>was<span style='letter-spacing:-.15pt'>
  </span>assessed<span style='letter-spacing:-.1pt'> </span>separately<span
  style='letter-spacing:-.2pt'> </span>from<span style='letter-spacing:-.25pt'>
  </span>general<span style='letter-spacing:-.25pt'> </span>reports<span
  style='letter-spacing:-.25pt'> </span>of<span style='letter-spacing:-.15pt'> </span>AEs.</span></p>
  <p class=TableParagraph style='margin-top:6.05pt;margin-right:6.05pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>Actual values and changes from pretreatment are
  summarized by study time point for safety laboratories, vital signs,<span
  style='letter-spacing:-2.4pt'> </span>and<span style='letter-spacing:-.05pt'>
  </span>ECGs.</span></p>
  </td>
 </tr>
 <tr style='height:376.5pt'>
  <td width=639 colspan=3 valign=top style='width:478.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:376.5pt'>
  <p class=TableParagraph style='margin-top:3.0pt'><b><span style='font-size:
  10.0pt'>Results:</span></b></p>
  <p class=TableParagraph style='margin-top:5.95pt'><b><i><span
  style='font-size:10.0pt'>Demographics<span style='letter-spacing:-.25pt'> </span>and<span
  style='letter-spacing:-.15pt'> </span>Baseline<span style='letter-spacing:
  -.2pt'> </span>Characteristics</span></i></b></p>
  <p class=TableParagraph style='margin-top:5.9pt;margin-right:15.8pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>A total of 8 subjects were treated with icatibant: 3
  subjects self-administered icatibant and 5 subjects had icatibant<span
  style='letter-spacing:-2.35pt'> </span>administered<span style='letter-spacing:
  -.05pt'> </span>by an<span style='letter-spacing:-.05pt'> </span>HCP.</span></p>
  <p class=TableParagraph style='margin-right:8.6pt'><span style='font-size:
  10.0pt;letter-spacing:-.05pt'>The</span><span style='font-size:10.0pt;
  letter-spacing:-.5pt'> </span><span style='font-size:10.0pt;letter-spacing:
  -.05pt'>mean</span><span style='font-size:10.0pt;letter-spacing:-.6pt'> </span><span
  style='font-size:10.0pt;letter-spacing:-.05pt'>(SD)</span><span
  style='font-size:10.0pt;letter-spacing:-.55pt'> </span><span
  style='font-size:10.0pt;letter-spacing:-.05pt'>age</span><span
  style='font-size:10.0pt;letter-spacing:-.55pt'> </span><span
  style='font-size:10.0pt;letter-spacing:-.05pt'>was</span><span
  style='font-size:10.0pt;letter-spacing:-.6pt'> </span><span style='font-size:
  10.0pt;letter-spacing:-.05pt'>45.5</span><span style='font-size:10.0pt;
  letter-spacing:-.55pt'> </span><span style='font-size:10.0pt;letter-spacing:
  -.05pt'>(16.9)</span><span style='font-size:10.0pt;letter-spacing:-.55pt'> </span><span
  style='font-size:10.0pt;letter-spacing:-.05pt'>years</span><span
  style='font-size:10.0pt;letter-spacing:-.6pt'> </span><span style='font-size:
  10.0pt;letter-spacing:-.05pt'>(range</span><span style='font-size:10.0pt;
  letter-spacing:-.55pt'> </span><span style='font-size:10.0pt;letter-spacing:
  -.05pt'>28.3</span><span style='font-size:10.0pt;letter-spacing:-.6pt'> </span><span
  style='font-size:10.0pt'>to<span style='letter-spacing:-.5pt'> </span>78.0).<span
  style='letter-spacing:-.6pt'> </span>Seven<span style='letter-spacing:-.55pt'>
  </span>(87.5%)<span style='letter-spacing:-.55pt'> </span>of<span
  style='letter-spacing:-.6pt'> </span>8<span style='letter-spacing:-.55pt'> </span>subjects<span
  style='letter-spacing:-.55pt'> </span>were<span style='letter-spacing:-.6pt'>
  </span>in<span style='letter-spacing:-.5pt'> </span>the<span
  style='letter-spacing:-.6pt'> </span>&#8804;65-year-old<span
  style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>age</span><span
  style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>group.</span><span
  style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>All</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>subjects</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>were</span><span
  style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.05pt'>Asian,</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>and</span><span
  style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>5</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>were</span><span
  style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>female</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>(62.5%).</span><span
  style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>The</span><span
  style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.05pt'>mean</span><span
  style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.05pt'>(SD)</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>weight</span><span
  style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>was</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>72.0</span><span
  style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>(20.3)</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>kg</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>(range</span><span
  style='letter-spacing:-.5pt'> </span>47.3<span style='letter-spacing:.05pt'> </span><span
  style='letter-spacing:-.05pt'>to 108.0), and 4 (50%) subjects were in the
  &gt;50 </span>to 75 kg weight category. The mean (SD) height was 162.0 (7.8)
  cm<span style='letter-spacing:-2.35pt'> </span>(range<span style='letter-spacing:
  -.4pt'> </span>150.0<span style='letter-spacing:-.4pt'> </span>to<span
  style='letter-spacing:-.4pt'> </span>176.0),<span style='letter-spacing:-.4pt'>
  </span>and<span style='letter-spacing:-.4pt'> </span>the<span
  style='letter-spacing:-.35pt'> </span>mean<span style='letter-spacing:-.4pt'>
  </span>(SD)<span style='letter-spacing:-.4pt'> </span>body<span
  style='letter-spacing:-.4pt'> </span>mass<span style='letter-spacing:-.35pt'>
  </span>index<span style='letter-spacing:-.4pt'> </span>(BMI)<span
  style='letter-spacing:-.4pt'> </span>was<span style='letter-spacing:-.4pt'> </span>27.4<span
  style='letter-spacing:-.4pt'> </span>(7.3)<span style='letter-spacing:-.5pt'>
  </span>kg/m<sup>2</sup><span style='letter-spacing:-.45pt'> </span>(range<span
  style='letter-spacing:-.4pt'> </span>19.3<span style='letter-spacing:-.4pt'> </span>to<span
  style='letter-spacing:-.4pt'> </span>36.3).</span></p>
  <p class=TableParagraph style='margin-right:14.65pt'><span style='font-size:
  10.0pt'>Hereditary angioedema history was summarized for the treated
  population. Four (50.0%) of 8 subjects reported a<span style='letter-spacing:
  .05pt'> </span>family history of HAE. The mean (SD) time since diagnosis was
  10.16 (9.21) years, and the mean (SD) time since<span style='letter-spacing:
  -2.35pt'> </span>the<span style='letter-spacing:-.05pt'> </span>last<span
  style='letter-spacing:-.05pt'> </span>attack<span style='letter-spacing:-.05pt'>
  </span>was<span style='letter-spacing:-.05pt'> </span>3.98<span
  style='letter-spacing:-.05pt'> </span>(2.61) months.</span></p>
  <p class=TableParagraph style='margin-right:13.05pt'><span style='font-size:
  10.0pt'>The on-study HAE attack was summarized for the treated population. A
  total of 4 (50.0%) subjects were<span style='letter-spacing:.05pt'> </span>experiencing
  a cutaneous attack, 3 (37.5%) subjects were experiencing an abdominal attack,
  and 1 (12.5%) subject<span style='letter-spacing:-2.35pt'> </span>experienced
  a laryngeal attack. All 8 (100.0%) treated subjects completed the study. The
  mean time (SD) from<span style='letter-spacing:.05pt'> </span>attack onset to
  study drug administration was 6.50 (2.37) hours (range 3.1 to 10.0). The
  administration method<span style='letter-spacing:.05pt'> </span>groups<span
  style='letter-spacing:-.1pt'> </span>were similar with respect to<span
  style='letter-spacing:.05pt'> </span>on-study HAE<span style='letter-spacing:
  -.05pt'> </span>attacks.</span></p>
  <p class=TableParagraph><span style='font-size:10.0pt'>A<span
  style='letter-spacing:-.15pt'> </span>total<span style='letter-spacing:-.2pt'>
  </span>of<span style='letter-spacing:-.2pt'> </span>6<span style='letter-spacing:
  -.15pt'> </span>(75.0%)<span style='letter-spacing:-.15pt'> </span>of<span
  style='letter-spacing:-.2pt'> </span>8<span style='letter-spacing:-.1pt'> </span>subjects<span
  style='letter-spacing:-.15pt'> </span>used<span style='letter-spacing:-.2pt'>
  </span>a<span style='letter-spacing:-.1pt'> </span>concomitant<span
  style='letter-spacing:-.1pt'> </span>medication<span style='letter-spacing:
  -.15pt'> </span>during<span style='letter-spacing:-.1pt'> </span>their<span
  style='letter-spacing:-.25pt'> </span>participation<span style='letter-spacing:
  -.1pt'> </span>in<span style='letter-spacing:-.1pt'> </span>the<span
  style='letter-spacing:-.15pt'> </span>trial.</span></p>
  <p class=TableParagraph style='margin-top:6.05pt;margin-right:5.2pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><u><span
  style='font-size:10.0pt'>Rescue Medication:</span></u><span style='font-size:
  10.0pt'> One subject used a medication designated by the investigator as
  rescue medication. However,<span style='letter-spacing:.05pt'> </span>this
  medication does not meet the protocol definition of rescue medication as it
  was given for a new abdominal HAE<span style='letter-spacing:-2.4pt'> </span>attack<span
  style='letter-spacing:-.05pt'> </span>of<span style='letter-spacing:-.05pt'> </span>moderate
  severity<span style='letter-spacing:-.05pt'> </span>that<span
  style='letter-spacing:-.05pt'> </span>occurred more<span style='letter-spacing:
  -.05pt'> </span>than<span style='letter-spacing:-.1pt'> </span>48<span
  style='letter-spacing:-.05pt'> </span>hours<span style='letter-spacing:-.05pt'>
  </span>after<span style='letter-spacing:-.05pt'> </span>the initial<span
  style='letter-spacing:-.05pt'> </span>attack.</span></p>
  <p class=TableParagraph style='margin-top:6.1pt'><b><i><span
  style='font-size:10.0pt'>Efficacy<span style='letter-spacing:-.1pt'> </span>Results</span></i></b></p>
  <p class=TableParagraph style='margin-top:5.95pt'><b><u><span
  style='font-size:10.0pt'>Primary<span style='letter-spacing:-.25pt'> </span>Efficacy<span
  style='letter-spacing:-.25pt'> </span>Endpoint</span></u></b></p>
  <p class=TableParagraph style='margin-top:5.9pt'><u><span style='font-size:
  10.0pt'>Time<span style='letter-spacing:-.15pt'> </span>to<span
  style='letter-spacing:-.15pt'> </span>Onset<span style='letter-spacing:-.25pt'>
  </span>of<span style='letter-spacing:-.2pt'> </span>Symptom<span
  style='letter-spacing:-.25pt'> </span>Relief:</span></u><span
  style='font-size:10.0pt;letter-spacing:-.15pt'> </span><span
  style='font-size:10.0pt'>TOSR<span style='letter-spacing:-.25pt'> </span>was<span
  style='letter-spacing:-.15pt'> </span>determined<span style='letter-spacing:
  -.15pt'> </span>retrospectively<span style='letter-spacing:-.25pt'> </span>as<span
  style='letter-spacing:-.15pt'> </span>the<span style='letter-spacing:-.15pt'>
  </span>earliest<span style='letter-spacing:-.25pt'> </span>of<span
  style='letter-spacing:-.2pt'> </span>3<span style='letter-spacing:-.15pt'> </span>consecutive</span></p>
  <p class=TableParagraph style='margin-top:.05pt;margin-right:11.85pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>non-missing measurements in which there was at least
  a 50% reduction in the pretreatment composite VAS score.<span
  style='letter-spacing:.05pt'> </span>All 8 (100%) subjects experienced
  symptom relief. The median TOSR was 1.75 hours (95% CI: 1.00, 2.50). At 1.5<span
  style='letter-spacing:-2.35pt'> </span>hours post-treatment, 4 (50%) of 8 subjects
  had experienced symptom relief and at 2.5 hours post-treatment, 7<span
  style='letter-spacing:.05pt'> </span>(87.5%)<span style='letter-spacing:-.1pt'>
  </span>of<span style='letter-spacing:-.05pt'> </span>8<span style='letter-spacing:
  -.05pt'> </span>subjects<span style='letter-spacing:-.05pt'> </span>had
  experienced<span style='letter-spacing:-.05pt'> </span>symptom<span
  style='letter-spacing:-.1pt'> </span>relief.</span></p>
  </td>
 </tr>
</table>

</div>

<span style='font-size:10.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection6>

<p class=MsoNormal style='margin-top:.1pt'><b><span style='font-size:2.5pt'>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.85pt;border-collapse:collapse;border:none'>
 <tr style='height:35.0pt'>
  <td width=200 valign=top style='width:150.1pt;border:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:35.0pt'>
  <p class=TableParagraph style='margin-top:2.95pt'><b><span style='font-size:
  10.0pt'>Name<span style='letter-spacing:-.3pt'> </span>of<span
  style='letter-spacing:-.15pt'> </span>sponsor/company:</span></b></p>
  <p class=TableParagraph style='margin-top:5.9pt'><span style='font-size:10.0pt'>Shire</span></p>
  </td>
  <td width=245 rowspan=3 valign=top style='width:183.95pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:35.0pt'>
  <p class=TableParagraph style='margin-top:2.8pt;margin-right:4.3pt;
  margin-bottom:0in;margin-left:5.4pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>Individual Study Table Referring to Part of<span
  style='letter-spacing:-2.4pt'> </span>the<span style='letter-spacing:-.05pt'>
  </span>Dossier</span></p>
  <p class=TableParagraph style='margin-top:6.05pt;margin-right:142.4pt;
  margin-bottom:0in;margin-left:5.4pt;margin-bottom:.0001pt;line-height:151%'><span
  style='font-size:10.0pt;line-height:151%;letter-spacing:-.05pt'>Volume:</span><span
  style='font-size:10.0pt;line-height:151%;letter-spacing:-2.35pt'> </span><span
  style='font-size:10.0pt;line-height:151%'>Page:</span></p>
  </td>
  <td width=193 rowspan=3 valign=top style='width:144.85pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:35.0pt'>
  <p class=TableParagraph style='margin-top:2.8pt;margin-right:26.55pt;
  margin-bottom:0in;margin-left:5.4pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>(for National Authority Use<span style='letter-spacing:
  -2.35pt'> </span>only)</span></p>
  </td>
 </tr>
 <tr style='height:34.95pt'>
  <td width=200 valign=top style='width:150.1pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:34.95pt'>
  <p class=TableParagraph style='margin-top:2.95pt'><b><span style='font-size:
  10.0pt'>Name<span style='letter-spacing:-.1pt'> </span>of<span
  style='letter-spacing:-.1pt'> </span>finished<span style='letter-spacing:
  -.05pt'> </span>product:</span></b></p>
  <p class=TableParagraph style='margin-top:5.9pt'><span style='font-size:10.0pt'>Firazyr<sup>®</sup></span></p>
  </td>
 </tr>
 <tr style='height:35.0pt'>
  <td width=200 valign=top style='width:150.1pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:35.0pt'>
  <p class=TableParagraph style='margin-top:3.0pt'><b><span style='font-size:
  10.0pt'>Name<span style='letter-spacing:-.15pt'> </span>of<span
  style='letter-spacing:-.15pt'> </span>active<span style='letter-spacing:-.05pt'>
  </span>ingredient:</span></b></p>
  <p class=TableParagraph style='margin-top:5.85pt'><span style='font-size:
  10.0pt'>icatibant</span></p>
  </td>
 </tr>
 <tr style='height:539.95pt'>
  <td width=639 colspan=3 valign=top style='width:478.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:539.95pt'>
  <p class=TableParagraph style='margin-top:2.95pt'><b><u><span
  style='font-size:10.0pt'>Key<span style='letter-spacing:-.2pt'> </span>Secondary<span
  style='letter-spacing:-.1pt'> </span>Endpoint</span></u></b></p>
  <p class=TableParagraph style='margin-top:2.9pt;margin-right:5.45pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt;letter-spacing:-.05pt'>The key secondary efficacy
  endpoint was the time to onset of primary symptom relief (TOSR-P). Primary
  symptom</span><span style='font-size:10.0pt'> <span style='letter-spacing:
  -.05pt'>relief</span><span style='letter-spacing:-.6pt'> </span><span
  style='letter-spacing:-.05pt'>was</span><span style='letter-spacing:-.55pt'> </span><span
  style='letter-spacing:-.05pt'>based</span><span style='letter-spacing:-.6pt'>
  </span><span style='letter-spacing:-.05pt'>on</span><span style='letter-spacing:
  -.55pt'> </span><span style='letter-spacing:-.05pt'>the</span><span
  style='letter-spacing:-.6pt'> </span><span style='letter-spacing:-.05pt'>subject-assessed</span><span
  style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>VAS</span><span
  style='letter-spacing:-.6pt'> </span><span style='letter-spacing:-.05pt'>score</span><span
  style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>for</span><span
  style='letter-spacing:-.6pt'> </span><span style='letter-spacing:-.05pt'>a</span><span
  style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>single</span><span
  style='letter-spacing:-.6pt'> </span><span style='letter-spacing:-.05pt'>primary</span><span
  style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>symptom,</span><span
  style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>determined</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>by</span><span
  style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>edema</span><span
  style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>location.</span><span
  style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>Time</span>
  <span style='letter-spacing:-.05pt'>to primary symptom relief is calculated
  from the </span>time of icatibant administration to the onset of primary
  symptom<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:
  -.1pt'>relief. Onset </span><span style='letter-spacing:-.05pt'>of primary
  symptom relief was determined retrospectively as the earliest of 3
  consecutive non-missing</span> measurements<span style='letter-spacing:-.5pt'>
  </span>in<span style='letter-spacing:-.45pt'> </span>which<span
  style='letter-spacing:-.5pt'> </span>there<span style='letter-spacing:-.45pt'>
  </span>is<span style='letter-spacing:-.45pt'> </span>a<span style='letter-spacing:
  -.5pt'> </span>reduction<span style='letter-spacing:-.45pt'> </span>less<span
  style='letter-spacing:-.45pt'> </span>than<span style='letter-spacing:-.5pt'>
  </span>Y=6/7<span style='letter-spacing:-.4pt'> </span>X<span
  style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.5pt'> </span>16<span
  style='letter-spacing:-.45pt'> </span>if<span style='letter-spacing:-.45pt'> </span>X<span
  style='letter-spacing:-.55pt'> </span>&#8805;30<span style='letter-spacing:
  -.5pt'> </span>or<span style='letter-spacing:-.5pt'> </span>68%<span
  style='letter-spacing:-.5pt'> </span>if<span style='letter-spacing:-.5pt'> </span>X<span
  style='letter-spacing:-.5pt'> </span>&lt;30<span style='letter-spacing:-.4pt'>
  </span>mm<span style='letter-spacing:-.55pt'> </span>in<span
  style='letter-spacing:-.5pt'> </span>the<span style='letter-spacing:-.4pt'> </span>pretreatment<span
  style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.1pt'>primary
  VAS score. All 8 (100%) subjects </span><span style='letter-spacing:-.05pt'>experienced
  primary symptom relief with administration of icatibant. The</span> <span
  style='letter-spacing:-.05pt'>median</span><span style='letter-spacing:-.55pt'>
  </span><span style='letter-spacing:-.05pt'>TOSR-P</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>was</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>1.07</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>hours</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>(95%</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>CI:</span><span
  style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>1.00,</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>2.00).</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>At</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>1.1</span><span
  style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>hours,</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>5</span><span
  style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>(62.5%)</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>of</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>8</span><span
  style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>subjects</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>had</span><span
  style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>experienced</span><span
  style='letter-spacing:-.5pt'> </span>symptom<span style='letter-spacing:.05pt'>
  </span>relief<span style='letter-spacing:-.35pt'> </span>and<span
  style='letter-spacing:-.35pt'> </span>at<span style='letter-spacing:-.4pt'> </span>2.0<span
  style='letter-spacing:-.35pt'> </span>hours<span style='letter-spacing:-.35pt'>
  </span>post-treatment,<span style='letter-spacing:-.35pt'> </span>7<span
  style='letter-spacing:-.35pt'> </span>(87.5%)<span style='letter-spacing:
  -.35pt'> </span>of<span style='letter-spacing:-.35pt'> </span>8<span
  style='letter-spacing:-.35pt'> </span>subjects<span style='letter-spacing:
  -.3pt'> </span>had<span style='letter-spacing:-.35pt'> </span>experienced<span
  style='letter-spacing:-.35pt'> </span>symptom<span style='letter-spacing:
  -.45pt'> </span>relief.</span></p>
  <p class=TableParagraph style='margin-top:6.1pt'><b><u><span
  style='font-size:10.0pt'>Other<span style='letter-spacing:-.1pt'> </span>Secondary
  Endpoints</span></u></b></p>
  <p class=TableParagraph style='margin-top:8.9pt;margin-right:5.45pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><u><span
  style='font-size:10.0pt'>Time to Almost Complete Symptom Relief:</span></u><span
  style='font-size:10.0pt'> Time to almost complete symptom relief (TACSR) was
  calculated from<span style='letter-spacing:-2.35pt'> </span>the time of
  icatibant administration to almost complete symptom relief. Almost complete
  symptom relief was<span style='letter-spacing:.05pt'> </span>determined<span
  style='letter-spacing:.1pt'> </span>retrospectively<span style='letter-spacing:
  .1pt'> </span>as<span style='letter-spacing:.05pt'> </span>the<span
  style='letter-spacing:.1pt'> </span>earliest of<span style='letter-spacing:
  .05pt'> </span>3<span style='letter-spacing:.1pt'> </span>consecutive<span
  style='letter-spacing:-.05pt'> </span>non-missing<span style='letter-spacing:
  .1pt'> </span>measurements<span style='letter-spacing:.1pt'> </span>for<span
  style='letter-spacing:.1pt'> </span>which<span style='letter-spacing:.1pt'> </span>all<span
  style='letter-spacing:.1pt'> </span>VAS<span style='letter-spacing:.1pt'> </span>scores<span
  style='letter-spacing:.05pt'> </span>were less than 10 mm. All 8 (100%)
  subjects experienced almost complete symptom relief. The median TACSR was<span
  style='letter-spacing:-2.35pt'> </span>5.98<span style='letter-spacing:-.1pt'>
  </span>hours<span style='letter-spacing:-.05pt'> </span>(95% CI:<span
  style='letter-spacing:-.1pt'> </span>1.50,<span style='letter-spacing:-.05pt'>
  </span>8.00).</span></p>
  <p class=TableParagraph style='margin-right:8.55pt'><u><span
  style='font-size:10.0pt'>Time to Initial Symptom Improvement Assessed by
  Investigator or Subject:</span></u><span style='font-size:10.0pt'>
  Investigators or subjects were asked to<span style='letter-spacing:.05pt'> </span>record
  the time at which they perceived initial improvement of symptoms. All 8
  (100%) subjects experienced initial<span style='letter-spacing:-2.35pt'> </span>symptom
  improvement. The median TISI as assessed by the investigator was 0.98 hour
  (95% CI: 0.30, 2.00). The<span style='letter-spacing:.05pt'> </span>median
  TISI as<span style='letter-spacing:-.05pt'> </span>assessed<span
  style='letter-spacing:-.05pt'> </span>by<span style='letter-spacing:-.05pt'> </span>the<span
  style='letter-spacing:-.05pt'> </span>subject was<span style='letter-spacing:
  -.05pt'> </span>1.04<span style='letter-spacing:-.05pt'> </span>hours (95%<span
  style='letter-spacing:-.1pt'> </span>CI: 0.30, 2.05).</span></p>
  <p class=TableParagraph style='margin-right:9.0pt'><u><span style='font-size:
  10.0pt'>Time to Onset of Symptom Relief for Individual VAS Symptoms:</span></u><span
  style='font-size:10.0pt'> Onset of symptom relief was determined<span
  style='letter-spacing:.05pt'> </span>retrospectively as the earliest of 3
  consecutive non-missing measurements in which there was at least a 50%<span
  style='letter-spacing:.05pt'> </span>reduction in the individual pretreatment
  VAS score. All subjects experienced TOSR for each individual VAS<span
  style='letter-spacing:.05pt'> </span>symptoms. The median TOSR for individual
  skin swelling was 1.97 hours (95% CI: 1.00, 6.00). The median TOSR<span
  style='letter-spacing:-2.35pt'> </span>for<span style='letter-spacing:-.1pt'>
  </span>individual<span style='letter-spacing:-.15pt'> </span>skin<span
  style='letter-spacing:-.15pt'> </span>pain<span style='letter-spacing:-.1pt'>
  </span>was<span style='letter-spacing:-.15pt'> </span>1.97<span
  style='letter-spacing:-.1pt'> </span>hours<span style='letter-spacing:-.1pt'>
  </span>(95%<span style='letter-spacing:-.15pt'> </span>CI:<span
  style='letter-spacing:-.05pt'> </span>1.00,<span style='letter-spacing:-.15pt'>
  </span>5.00).<span style='letter-spacing:-.1pt'> </span>The<span
  style='letter-spacing:-.1pt'> </span>median<span style='letter-spacing:-.1pt'>
  </span>TOSR<span style='letter-spacing:-.15pt'> </span>for<span
  style='letter-spacing:-.1pt'> </span>individual<span style='letter-spacing:
  -.05pt'> </span>abdominal<span style='letter-spacing:-.1pt'> </span>pain<span
  style='letter-spacing:-.1pt'> </span>was</span></p>
  <p class=TableParagraph style='margin-top:0in;margin-right:18.55pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>1.53 hours (95% CI: 1.00, 2.00). In 1 subject, who
  had a laryngeal HAE attack and was treated with icatibant, the<span
  style='letter-spacing:-2.35pt'> </span>TOSR<span style='letter-spacing:-.15pt'>
  </span>for<span style='letter-spacing:-.05pt'> </span>voice change<span
  style='letter-spacing:-.05pt'> </span>was<span style='letter-spacing:-.1pt'> </span>1
  hour.</span></p>
  <p class=TableParagraph style='margin-top:5.95pt'><u><span style='font-size:
  10.0pt'>Composite<span style='letter-spacing:-.1pt'> </span>VAS<span
  style='letter-spacing:-.05pt'> </span>Scores:</span></u><span
  style='font-size:10.0pt;letter-spacing:-.15pt'> </span><span
  style='font-size:10.0pt'>Composite<span style='letter-spacing:-.1pt'> </span>VAS<span
  style='letter-spacing:-.05pt'> </span>scores<span style='letter-spacing:-.15pt'>
  </span>were<span style='letter-spacing:-.05pt'> </span>calculated<span
  style='letter-spacing:-.05pt'> </span>as<span style='letter-spacing:-.15pt'> </span>the<span
  style='letter-spacing:-.05pt'> </span>average<span style='letter-spacing:
  -.1pt'> </span>of<span style='letter-spacing:-.1pt'> </span>VAS<span
  style='letter-spacing:-.05pt'> </span>measurements<span style='letter-spacing:
  -.1pt'> </span>for</span></p>
  <p class=TableParagraph style='margin-top:.05pt;margin-right:13.8pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>3-symptom composite scores for non-laryngeal attacks
  and 5 symptom composite scores for laryngeal attacks. The<span
  style='letter-spacing:-2.35pt'> </span>mean (SD) composite VAS score
  decreased 29.4 (13.0) from 30.8 (13.5) at pretreatment to 1.4 (1.8) at 8
  hours<span style='letter-spacing:.05pt'> </span>post-treatment.</span></p>
  <p class=TableParagraph style='margin-right:8.05pt'><u><span
  style='font-size:10.0pt'>Individual VAS scores:</span></u><span
  style='font-size:10.0pt'> The actual value for each individual VAS score
  (skin swelling, skin pain, abdominal pain,<span style='letter-spacing:.05pt'>
  </span>difficulty swallowing, voice change) change from pretreatment, and
  number and percentage of subjects with at least<span style='letter-spacing:
  -2.35pt'> </span>a 50% reduction from pretreatment by study time point are
  provided for the treated population. Each of the<span style='letter-spacing:
  .05pt'> </span>individual<span style='letter-spacing:-.15pt'> </span>VAS
  scores<span style='letter-spacing:-.05pt'> </span>decreased<span
  style='letter-spacing:-.05pt'> </span>over time.</span></p>
  <p class=TableParagraph style='margin-top:5.95pt;margin-right:6.9pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><u><span
  style='font-size:10.0pt'>Composite Symptom Scores:</span></u><span
  style='font-size:10.0pt'> Composite symptom scores (SS) were assessed by both
  the investigator and subject.<span style='letter-spacing:.05pt'> </span>The
  investigator-assessed composite SS was calculated as the average 8 symptoms
  for cutaneous and/or abdominal<span style='letter-spacing:.05pt'> </span>attacks
  and the average 13 symptoms for laryngeal attacks. The mean (SD)
  investigator-assessed composite SS<span style='letter-spacing:.05pt'> </span>decreased
  0.48 (0.28) from 0.59 (0.28) at pretreatment to 0.12 (0.18) at 8 hours
  post-treatment. The subject-assessed<span style='letter-spacing:-2.4pt'> </span>composite
  SS was calculated as the average of 8 symptoms for cutaneous and/or abdominal
  and the average 10<span style='letter-spacing:.05pt'> </span>symptoms<span
  style='letter-spacing:-.05pt'> </span>for<span style='letter-spacing:-.05pt'>
  </span>laryngeal attacks.<span style='letter-spacing:-.05pt'> </span>The mean<span
  style='letter-spacing:-.05pt'> </span>(SD)<span style='letter-spacing:-.05pt'>
  </span>subject-assessed<span style='letter-spacing:-.05pt'> </span>composite
  SS<span style='letter-spacing:-.1pt'> </span>decreased<span style='letter-spacing:
  -.1pt'> </span>0.54<span style='letter-spacing:-.1pt'> </span>(0.40)<span
  style='letter-spacing:-.05pt'> </span>from</span></p>
  <p class=TableParagraph style='margin-top:0in'><span style='font-size:10.0pt'>0.68<span
  style='letter-spacing:-.15pt'> </span>(0.41)<span style='letter-spacing:-.1pt'>
  </span>at<span style='letter-spacing:-.15pt'> </span>pretreatment<span
  style='letter-spacing:-.15pt'> </span>to<span style='letter-spacing:-.1pt'> </span>0.14<span
  style='letter-spacing:-.1pt'> </span>(0.16)<span style='letter-spacing:-.1pt'>
  </span>at<span style='letter-spacing:-.15pt'> </span>8<span style='letter-spacing:
  -.15pt'> </span>hours<span style='letter-spacing:-.15pt'> </span>post-treatment.</span></p>
  <p class=TableParagraph style='margin-top:6.05pt;line-height:10.65pt'><u><span
  style='font-size:10.0pt'>Individual<span style='letter-spacing:-.2pt'> </span>Symptom<span
  style='letter-spacing:-.2pt'> </span>Scores:</span></u><span
  style='font-size:10.0pt;letter-spacing:-.1pt'> </span><span style='font-size:
  10.0pt'>Individual<span style='letter-spacing:-.15pt'> </span>SS<span
  style='letter-spacing:-.15pt'> </span>were<span style='letter-spacing:-.15pt'>
  </span>assessed<span style='letter-spacing:-.1pt'> </span>by<span
  style='letter-spacing:-.15pt'> </span>both<span style='letter-spacing:-.1pt'>
  </span>the<span style='letter-spacing:-.1pt'> </span>investigator<span
  style='letter-spacing:-.05pt'> </span>and<span style='letter-spacing:-.1pt'> </span>subject.<span
  style='letter-spacing:-.15pt'> </span>The<span style='letter-spacing:-.1pt'> </span>investigator-<span
  style='letter-spacing:-.1pt'> </span>and</span></p>
  </td>
 </tr>
</table>

</div>

<span style='font-size:10.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection7>

<p class=MsoNormal style='margin-top:.1pt'><b><span style='font-size:2.5pt'>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.85pt;border-collapse:collapse;border:none'>
 <tr style='height:35.0pt'>
  <td width=200 valign=top style='width:150.1pt;border:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:35.0pt'>
  <p class=TableParagraph style='margin-top:2.95pt'><b><span style='font-size:
  10.0pt'>Name<span style='letter-spacing:-.3pt'> </span>of<span
  style='letter-spacing:-.15pt'> </span>sponsor/company:</span></b></p>
  <p class=TableParagraph style='margin-top:5.9pt'><span style='font-size:10.0pt'>Shire</span></p>
  </td>
  <td width=245 rowspan=3 valign=top style='width:183.95pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:35.0pt'>
  <p class=TableParagraph style='margin-top:2.8pt;margin-right:4.3pt;
  margin-bottom:0in;margin-left:5.4pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>Individual Study Table Referring to Part of<span
  style='letter-spacing:-2.4pt'> </span>the<span style='letter-spacing:-.05pt'>
  </span>Dossier</span></p>
  <p class=TableParagraph style='margin-top:6.05pt;margin-right:142.4pt;
  margin-bottom:0in;margin-left:5.4pt;margin-bottom:.0001pt;line-height:151%'><span
  style='font-size:10.0pt;line-height:151%;letter-spacing:-.05pt'>Volume:</span><span
  style='font-size:10.0pt;line-height:151%;letter-spacing:-2.35pt'> </span><span
  style='font-size:10.0pt;line-height:151%'>Page:</span></p>
  </td>
  <td width=193 rowspan=3 valign=top style='width:144.85pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:35.0pt'>
  <p class=TableParagraph style='margin-top:2.8pt;margin-right:26.55pt;
  margin-bottom:0in;margin-left:5.4pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>(for National Authority Use<span style='letter-spacing:
  -2.35pt'> </span>only)</span></p>
  </td>
 </tr>
 <tr style='height:34.95pt'>
  <td width=200 valign=top style='width:150.1pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:34.95pt'>
  <p class=TableParagraph style='margin-top:2.95pt'><b><span style='font-size:
  10.0pt'>Name<span style='letter-spacing:-.1pt'> </span>of<span
  style='letter-spacing:-.1pt'> </span>finished<span style='letter-spacing:
  -.05pt'> </span>product:</span></b></p>
  <p class=TableParagraph style='margin-top:5.9pt'><span style='font-size:10.0pt'>Firazyr<sup>®</sup></span></p>
  </td>
 </tr>
 <tr style='height:35.0pt'>
  <td width=200 valign=top style='width:150.1pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:35.0pt'>
  <p class=TableParagraph style='margin-top:3.0pt'><b><span style='font-size:
  10.0pt'>Name<span style='letter-spacing:-.15pt'> </span>of<span
  style='letter-spacing:-.15pt'> </span>active<span style='letter-spacing:-.05pt'>
  </span>ingredient:</span></b></p>
  <p class=TableParagraph style='margin-top:5.85pt'><span style='font-size:
  10.0pt'>icatibant</span></p>
  </td>
 </tr>
 <tr style='height:539.8pt'>
  <td width=639 colspan=3 valign=top style='width:478.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:539.8pt'>
  <p class=TableParagraph style='margin-top:0in;margin-right:6.55pt;margin-bottom:
  0in;margin-left:5.35pt;margin-bottom:.0001pt'><span style='font-size:10.0pt'>subject
  -assessed SS associated with individual symptoms were summarized by study
  time points.<span style='letter-spacing:.05pt'> </span>Each of the<span
  style='letter-spacing:.05pt'> </span>individual investigator- and subject
  -assessed SS decreased over time. Symptom severity scores were assessed using<span
  style='letter-spacing:-2.35pt'> </span>the using the 5-point scale where the
  symptoms are scored from 0 for absence of symptoms to 4 for very severe.<span
  style='letter-spacing:-2.35pt'> </span>For subjects<span style='letter-spacing:
  .05pt'> </span>that exhibited<span style='letter-spacing:.05pt'> </span>individual<span
  style='letter-spacing:.05pt'> </span>symptoms<span style='letter-spacing:
  .05pt'> </span>at pretreatment,<span style='letter-spacing:.05pt'> </span>the<span
  style='letter-spacing:.1pt'> </span>investigator-<span style='letter-spacing:
  .05pt'> </span>and subject -assessed<span style='letter-spacing:.05pt'> </span>SS<span
  style='letter-spacing:.05pt'> </span>decreased<span style='letter-spacing:
  -.1pt'> </span>over time,<span style='letter-spacing:-.05pt'> </span>signifying<span
  style='letter-spacing:.05pt'> </span>symptom<span style='letter-spacing:-.1pt'>
  </span>severity<span style='letter-spacing:-.05pt'> </span>improvement.</span></p>
  <p class=TableParagraph style='margin-top:5.85pt;margin-right:8.75pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><u><span
  style='font-size:10.0pt'>Global Assessment:</span></u><span style='font-size:
  10.0pt'> The location and severity of the attack was based on the
  investigator global assessment at<span style='letter-spacing:.05pt'> </span>pretreatment
  (baseline). The investigator made a global assessment (ie, consideration of
  all abdominal symptoms<span style='letter-spacing:.05pt'> </span>combined,
  all cutaneous symptoms combined and/or all laryngeal symptoms combined) using
  the following 5-point<span style='letter-spacing:-2.35pt'> </span>scale,<span
  style='letter-spacing:-.1pt'> </span>where<span style='letter-spacing:-.15pt'>
  </span>the<span style='letter-spacing:-.05pt'> </span>symptoms<span
  style='letter-spacing:-.05pt'> </span>were<span style='letter-spacing:-.05pt'>
  </span>scored<span style='letter-spacing:-.1pt'> </span>from<span
  style='letter-spacing:-.15pt'> </span>0<span style='letter-spacing:-.05pt'> </span>for<span
  style='letter-spacing:-.05pt'> </span>absence<span style='letter-spacing:
  -.05pt'> </span>of<span style='letter-spacing:-.05pt'> </span>symptoms<span
  style='letter-spacing:-.05pt'> </span>to<span style='letter-spacing:-.1pt'> </span>4<span
  style='letter-spacing:-.1pt'> </span>for<span style='letter-spacing:-.05pt'> </span>very<span
  style='letter-spacing:-.05pt'> </span>severe.</span></p>
  <p class=TableParagraph style='margin-right:7.95pt'><span style='font-size:
  10.0pt'>For the global assessment of cutaneous symptoms, the investigators
  assessed 3 (37.5%) subjects as having no<span style='letter-spacing:.05pt'> </span>symptoms,
  4 (50.0%) subjects as having moderate symptoms, and 1 (12.5%) subject as
  having severe symptoms at<span style='letter-spacing:.05pt'> </span>pretreatment.
  The global assessment of cutaneous symptom severity improved over time. At 8
  hours post-treatment,<span style='letter-spacing:-2.35pt'> </span>4<span
  style='letter-spacing:-.1pt'> </span>(50.0%)<span style='letter-spacing:-.05pt'>
  </span>subjects reported<span style='letter-spacing:-.1pt'> </span>no
  symptoms<span style='letter-spacing:-.05pt'> </span>and<span
  style='letter-spacing:-.05pt'> </span>4<span style='letter-spacing:-.1pt'> </span>(50%)
  subjects<span style='letter-spacing:-.05pt'> </span>reported<span
  style='letter-spacing:-.1pt'> </span>mild symptoms.</span></p>
  <p class=TableParagraph><span style='font-size:10.0pt'>For the global
  assessment of abdominal symptoms, the investigators assessed 4 (50.0%)
  subjects as having no<span style='letter-spacing:.05pt'> </span>symptoms, 1
  (12.5%) subjects as having mild symptoms, 2 (25.0%) subjects as having
  moderate symptoms, and 1<span style='letter-spacing:.05pt'> </span>(12.5%)<span
  style='letter-spacing:-.15pt'> </span>subject<span style='letter-spacing:
  -.15pt'> </span>as<span style='letter-spacing:-.15pt'> </span>having<span
  style='letter-spacing:-.1pt'> </span>severe<span style='letter-spacing:-.1pt'>
  </span>symptoms<span style='letter-spacing:-.15pt'> </span>at<span
  style='letter-spacing:-.15pt'> </span>pretreatment.<span style='letter-spacing:
  -.15pt'> </span>The<span style='letter-spacing:-.15pt'> </span>global<span
  style='letter-spacing:-.2pt'> </span>assessment<span style='letter-spacing:
  -.15pt'> </span>of<span style='letter-spacing:-.15pt'> </span>abdominal<span
  style='letter-spacing:-.15pt'> </span>symptom<span style='letter-spacing:
  -.2pt'> </span>severity<span style='letter-spacing:-2.35pt'> </span>improved<span
  style='letter-spacing:-.1pt'> </span>over<span style='letter-spacing:-.15pt'>
  </span>time.<span style='letter-spacing:-.05pt'> </span>By<span
  style='letter-spacing:-.1pt'> </span>4<span style='letter-spacing:-.05pt'> </span>hours<span
  style='letter-spacing:-.05pt'> </span>post-treatment,<span style='letter-spacing:
  -.05pt'> </span>all<span style='letter-spacing:-.05pt'> </span>8<span
  style='letter-spacing:-.05pt'> </span>(100.0%)<span style='letter-spacing:
  -.05pt'> </span>subjects<span style='letter-spacing:-.05pt'> </span>reported<span
  style='letter-spacing:-.05pt'> </span>no<span style='letter-spacing:-.05pt'> </span>symptoms.</span></p>
  <p class=TableParagraph style='margin-top:5.95pt'><span style='font-size:
  10.0pt'>For the global assessment of laryngeal symptoms, the investigators
  assessed 7 (87.5%) subjects as having no<span style='letter-spacing:.05pt'> </span>symptoms,
  and 1 (12.5%) subject as having mild symptoms at pretreatment. The global
  assessment of laryngeal<span style='letter-spacing:.05pt'> </span>symptom<span
  style='letter-spacing:-.2pt'> </span>severity<span style='letter-spacing:
  -.2pt'> </span>improved<span style='letter-spacing:-.15pt'> </span>over<span
  style='letter-spacing:-.15pt'> </span>time.<span style='letter-spacing:-.1pt'>
  </span>By<span style='letter-spacing:-.15pt'> </span>2<span style='letter-spacing:
  -.15pt'> </span>hours<span style='letter-spacing:-.15pt'> </span>post-treatment,<span
  style='letter-spacing:-.1pt'> </span>all<span style='letter-spacing:-.15pt'> </span>8<span
  style='letter-spacing:-.1pt'> </span>(100.0%)<span style='letter-spacing:
  -.15pt'> </span>subjects<span style='letter-spacing:-.15pt'> </span>reported<span
  style='letter-spacing:-.15pt'> </span>no<span style='letter-spacing:-.15pt'> </span>symptoms.</span></p>
  <p class=TableParagraph><span style='font-size:10.0pt'>In<span
  style='letter-spacing:-.1pt'> </span>all<span style='letter-spacing:-.1pt'> </span>subjects,<span
  style='letter-spacing:-.2pt'> </span>only<span style='letter-spacing:-.1pt'> </span>a<span
  style='letter-spacing:-.2pt'> </span>single<span style='letter-spacing:-.1pt'>
  </span>SC<span style='letter-spacing:-.1pt'> </span>30<span style='letter-spacing:
  -.1pt'> </span>mg<span style='letter-spacing:-.1pt'> </span>dose<span
  style='letter-spacing:-.2pt'> </span>of<span style='letter-spacing:-.1pt'> </span>icatibant<span
  style='letter-spacing:-.2pt'> </span>was<span style='letter-spacing:-.1pt'> </span>required.</span></p>
  <p class=TableParagraph style='margin-top:6.15pt'><b><u><span
  style='font-size:10.0pt'>Other<span style='letter-spacing:-.15pt'> </span>Observations<span
  style='letter-spacing:-.15pt'> </span>Related<span style='letter-spacing:
  -.15pt'> </span>to<span style='letter-spacing:-.05pt'> </span>Efficacy</span></u></b></p>
  <p class=TableParagraph style='margin-top:5.9pt;margin-right:11.7pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><u><span
  style='font-size:10.0pt'>Self-administration<span style='letter-spacing:-.25pt'>
  </span>of<span style='letter-spacing:-.2pt'> </span>Study<span
  style='letter-spacing:-.25pt'> </span>Drug:</span></u><span style='font-size:
  10.0pt;letter-spacing:-.25pt'> </span><span style='font-size:10.0pt'>The<span
  style='letter-spacing:-.15pt'> </span>primary<span style='letter-spacing:
  -.2pt'> </span>and<span style='letter-spacing:-.2pt'> </span>key<span
  style='letter-spacing:-.2pt'> </span>secondary<span style='letter-spacing:
  -.25pt'> </span>endpoints<span style='letter-spacing:-.25pt'> </span>were<span
  style='letter-spacing:-.2pt'> </span>similar<span style='letter-spacing:-.15pt'>
  </span>between<span style='letter-spacing:-.15pt'> </span>administration<span
  style='letter-spacing:.05pt'> </span>method groups. The median TOSR was
  similar between subjects who self-administered icatibant (median: 1.53<span
  style='letter-spacing:.05pt'> </span>hours; 95% CI: 1.52, 2.50) and subjects
  who had icatibant administered by an HCP (median: 1.97 hours; 95% CI:<span
  style='letter-spacing:.05pt'> </span>1.00,<span style='letter-spacing:-.15pt'>
  </span>5.00).<span style='letter-spacing:-.1pt'> </span>The<span
  style='letter-spacing:-.05pt'> </span>administration<span style='letter-spacing:
  -.05pt'> </span>method<span style='letter-spacing:-.15pt'> </span>groups<span
  style='letter-spacing:-.1pt'> </span>were<span style='letter-spacing:-.1pt'> </span>generally<span
  style='letter-spacing:-.1pt'> </span>similar<span style='letter-spacing:-.1pt'>
  </span>with<span style='letter-spacing:-.1pt'> </span>all<span
  style='letter-spacing:-.05pt'> </span>other<span style='letter-spacing:-.05pt'>
  </span>secondary<span style='letter-spacing:-.1pt'> </span>endpoints.</span></p>
  <p class=TableParagraph style='margin-top:6.1pt'><b><i><span
  style='font-size:10.0pt'>Pharmacokinetic<span style='letter-spacing:-.35pt'> </span>Results</span></i></b></p>
  <p class=TableParagraph style='margin-top:5.9pt;margin-right:6.85pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>Observed mean (SD) plasma concentrations, at 0.75
  and 2 hours post a single SC administration of icatibant were<span
  style='letter-spacing:.05pt'> </span>352 (265) and 366 (131) ng/mL for
  icatibant, 166 (61.6) and 286 (49.1) ng/mL for M1, and 729 (563) and 386
  (122)<span style='letter-spacing:-2.35pt'> </span>ng/mL for M2, respectively.
  The corresponding molar ratios between M1 to icatibant and M2 to icatibant
  are<span style='letter-spacing:.05pt'> </span>approximately 1.90 (0.698) and
  2.93 (1.89) at 2 hours post-dose, indicating that higher levels of M1 and M2
  in the<span style='letter-spacing:.05pt'> </span>circulation<span
  style='letter-spacing:-.05pt'> </span>in<span style='letter-spacing:.05pt'> </span>this<span
  style='letter-spacing:-.1pt'> </span>population</span><span style='font-size:
  12.0pt'>.</span></p>
  <p class=TableParagraph style='margin-top:5.95pt;margin-right:7.5pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>Icatibant was absorbed in adult Japanese HAE
  subjects with a time of maximum observed plasma concentration<span
  style='letter-spacing:.05pt'> </span>(t<sub>max</sub>) median of 1.90 hours
  (min-max: 1.2-2.6 hours). The mean (SD) C<sub>max</sub> was 405 (194) ng/mL
  and the mean (SD)<span style='letter-spacing:-2.35pt'> </span><span
  style='letter-spacing:-.05pt'>AUC<sub>0-6</sub> was 1506 (509) ngh/mL. The
  mean (SD) elimination </span>half-life (T<sub>1/2&#946;</sub>) was 2.86
  (0.17) hours. The mean (SD)<span style='letter-spacing:.05pt'> </span>systemic<span
  style='letter-spacing:-.1pt'> </span>clearance<span style='letter-spacing:
  -.1pt'> </span>was<span style='letter-spacing:-.15pt'> </span>17.5<span
  style='letter-spacing:-.05pt'> </span>(4.37)<span style='letter-spacing:-.1pt'>
  </span>L/h<span style='letter-spacing:-.05pt'> </span>and<span
  style='letter-spacing:-.15pt'> </span>the<span style='letter-spacing:-.1pt'> </span>mean<span
  style='letter-spacing:-.05pt'> </span>(SD)<span style='letter-spacing:-.2pt'>
  </span>central<span style='letter-spacing:-.15pt'> </span>volume<span
  style='letter-spacing:-.05pt'> </span>of<span style='letter-spacing:-.1pt'> </span>distribution<span
  style='letter-spacing:-.15pt'> </span>was<span style='letter-spacing:-.15pt'>
  </span>31.4<span style='letter-spacing:-.1pt'> </span>(12.1)<span
  style='letter-spacing:-.1pt'> </span>L.</span></p>
  <p class=TableParagraph style='margin-top:6.05pt;margin-right:7.4pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>Systemic exposure to icatibant in Japanese subjects
  residing in Japan was demonstrated. Icatibant was absorbed in<span
  style='letter-spacing:.05pt'> </span>Japanese HAE patients. However, the
  exposure to icatibant in Japanese patients with HAE following a single 30 mg<span
  style='letter-spacing:-2.35pt'> </span>dose<span style='letter-spacing:-.1pt'>
  </span>was<span style='letter-spacing:-.1pt'> </span>generally<span
  style='letter-spacing:-.1pt'> </span>lower<span style='letter-spacing:-.05pt'>
  </span>than<span style='letter-spacing:-.1pt'> </span>that<span
  style='letter-spacing:-.1pt'> </span>observed<span style='letter-spacing:
  -.05pt'> </span>in<span style='letter-spacing:-.1pt'> </span>adult<span
  style='letter-spacing:-.1pt'> </span>Japanese<span style='letter-spacing:
  -.05pt'> </span>healthy<span style='letter-spacing:-.1pt'> </span>subjects<span
  style='letter-spacing:-.05pt'> </span>residing<span style='letter-spacing:
  -.1pt'> </span>in<span style='letter-spacing:-.05pt'> </span>the<span
  style='letter-spacing:-.15pt'> </span>US<span style='letter-spacing:-.05pt'> </span>and<span
  style='letter-spacing:-.05pt'> </span>adult</span></p>
  <p class=TableParagraph style='margin-top:0in;margin-right:8.0pt;margin-bottom:
  0in;margin-left:5.35pt;margin-bottom:.0001pt;line-height:11.5pt'><span
  style='font-size:10.0pt'>non-Japanese subjects, predominantly Caucasian
  healthy volunteers, as well as non-Japanese subjects with HAE.<span
  style='letter-spacing:.05pt'> </span>The<span style='letter-spacing:-.1pt'> </span>lower<span
  style='letter-spacing:-.1pt'> </span>exposure<span style='letter-spacing:
  -.1pt'> </span>in<span style='letter-spacing:-.05pt'> </span>Japanese<span
  style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:
  -.15pt'> </span>with<span style='letter-spacing:-.05pt'> </span>HAE<span
  style='letter-spacing:-.15pt'> </span>did<span style='letter-spacing:-.1pt'> </span>not<span
  style='letter-spacing:-.2pt'> </span>affect<span style='letter-spacing:-.15pt'>
  </span>the<span style='letter-spacing:-.1pt'> </span>efficacy<span
  style='letter-spacing:-.15pt'> </span>response,<span style='letter-spacing:
  -.15pt'> </span>regardless<span style='letter-spacing:-.1pt'> </span>of<span
  style='letter-spacing:-.15pt'> </span>administration</span></p>
  </td>
 </tr>
</table>

</div>

<span style='font-size:10.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection8>

<p class=MsoNormal style='margin-top:.1pt'><b><span style='font-size:2.5pt'>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.85pt;border-collapse:collapse;border:none'>
 <tr style='height:35.0pt'>
  <td width=200 valign=top style='width:150.1pt;border:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:35.0pt'>
  <p class=TableParagraph style='margin-top:2.95pt'><b><span style='font-size:
  10.0pt'>Name<span style='letter-spacing:-.3pt'> </span>of<span
  style='letter-spacing:-.15pt'> </span>sponsor/company:</span></b></p>
  <p class=TableParagraph style='margin-top:5.9pt'><span style='font-size:10.0pt'>Shire</span></p>
  </td>
  <td width=245 rowspan=3 valign=top style='width:183.95pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:35.0pt'>
  <p class=TableParagraph style='margin-top:2.8pt;margin-right:4.3pt;
  margin-bottom:0in;margin-left:5.4pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>Individual Study Table Referring to Part of<span
  style='letter-spacing:-2.4pt'> </span>the<span style='letter-spacing:-.05pt'>
  </span>Dossier</span></p>
  <p class=TableParagraph style='margin-top:6.05pt;margin-right:142.4pt;
  margin-bottom:0in;margin-left:5.4pt;margin-bottom:.0001pt;line-height:151%'><span
  style='font-size:10.0pt;line-height:151%;letter-spacing:-.05pt'>Volume:</span><span
  style='font-size:10.0pt;line-height:151%;letter-spacing:-2.35pt'> </span><span
  style='font-size:10.0pt;line-height:151%'>Page:</span></p>
  </td>
  <td width=193 rowspan=3 valign=top style='width:144.85pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:35.0pt'>
  <p class=TableParagraph style='margin-top:2.8pt;margin-right:26.55pt;
  margin-bottom:0in;margin-left:5.4pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>(for National Authority Use<span style='letter-spacing:
  -2.35pt'> </span>only)</span></p>
  </td>
 </tr>
 <tr style='height:34.95pt'>
  <td width=200 valign=top style='width:150.1pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:34.95pt'>
  <p class=TableParagraph style='margin-top:2.95pt'><b><span style='font-size:
  10.0pt'>Name<span style='letter-spacing:-.1pt'> </span>of<span
  style='letter-spacing:-.1pt'> </span>finished<span style='letter-spacing:
  -.05pt'> </span>product:</span></b></p>
  <p class=TableParagraph style='margin-top:5.9pt'><span style='font-size:10.0pt'>Firazyr<sup>®</sup></span></p>
  </td>
 </tr>
 <tr style='height:35.0pt'>
  <td width=200 valign=top style='width:150.1pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:35.0pt'>
  <p class=TableParagraph style='margin-top:3.0pt'><b><span style='font-size:
  10.0pt'>Name<span style='letter-spacing:-.15pt'> </span>of<span
  style='letter-spacing:-.15pt'> </span>active<span style='letter-spacing:-.05pt'>
  </span>ingredient:</span></b></p>
  <p class=TableParagraph style='margin-top:5.85pt'><span style='font-size:
  10.0pt'>icatibant</span></p>
  </td>
 </tr>
 <tr style='height:268.95pt'>
  <td width=639 colspan=3 valign=top style='width:478.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:268.95pt'>
  <p class=TableParagraph style='margin-top:0in;text-align:justify;line-height:
  11.35pt'><span style='font-size:10.0pt'>method,<span style='letter-spacing:
  -.15pt'> </span>since<span style='letter-spacing:-.1pt'> </span>the<span
  style='letter-spacing:-.1pt'> </span>median<span style='letter-spacing:-.05pt'>
  </span>TOSR<span style='letter-spacing:-.15pt'> </span>was<span
  style='letter-spacing:-.1pt'> </span>1.75<span style='letter-spacing:-.15pt'>
  </span>hours<span style='letter-spacing:-.05pt'> </span>and<span
  style='letter-spacing:-.15pt'> </span>7<span style='letter-spacing:-.1pt'> </span>(87.5%)<span
  style='letter-spacing:-.1pt'> </span>of<span style='letter-spacing:-.15pt'> </span>8<span
  style='letter-spacing:-.05pt'> </span>subjects<span style='letter-spacing:
  -.1pt'> </span>experienced<span style='letter-spacing:-.05pt'> </span>symptom<span
  style='letter-spacing:-.2pt'> </span>relief<span style='letter-spacing:-.1pt'>
  </span>by</span></p>
  <p class=TableParagraph style='margin-top:0in'><span style='font-size:10.0pt'>2.5<span
  style='letter-spacing:-.2pt'> </span>hours.<span style='letter-spacing:-.2pt'>
  </span>All<span style='letter-spacing:-.15pt'> </span>subjects<span
  style='letter-spacing:-.2pt'> </span>displayed<span style='letter-spacing:
  -.2pt'> </span>resolution<span style='letter-spacing:-.1pt'> </span>of<span
  style='letter-spacing:-.15pt'> </span>symptoms<span style='letter-spacing:
  -.1pt'> </span>within<span style='letter-spacing:-.2pt'> </span>5<span
  style='letter-spacing:-.2pt'> </span>hours<span style='letter-spacing:-.2pt'>
  </span>of<span style='letter-spacing:-.25pt'> </span>icatibant<span
  style='letter-spacing:-.1pt'> </span>treatment.</span></p>
  <p class=TableParagraph style='margin-top:6.15pt;text-align:justify'><b><i><span
  style='font-size:10.0pt'>Safety<span style='letter-spacing:-.2pt'> </span>Results</span></i></b></p>
  <p class=TableParagraph style='margin-top:5.85pt;margin-right:17.6pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt;text-align:justify'><span
  style='font-size:10.0pt'>There were a total of 3 TEAEs in 3 (37.5%) of 8
  subjects. Two (25%) subjects experienced TEAEs of HAE and 1<span
  style='letter-spacing:-2.35pt'> </span>(12.5%) subject experienced a TEAE of
  a headache. The 3 TEAEs reported in this study were assessed as mild in<span
  style='letter-spacing:-2.35pt'> </span>intensity<span style='letter-spacing:
  -.05pt'> </span>and<span style='letter-spacing:-.05pt'> </span>not related<span
  style='letter-spacing:-.05pt'> </span>to<span style='letter-spacing:.05pt'> </span>the
  study<span style='letter-spacing:-.05pt'> </span>drug<span style='letter-spacing:
  -.05pt'> </span>by the investigator.</span></p>
  <p class=TableParagraph style='margin-right:5.7pt;text-align:justify'><span
  style='font-size:10.0pt'>Seven (87.5%) of 8 subjects experienced an injection
  site reaction. The most frequently noted injection site reactions<span
  style='letter-spacing:-2.35pt'> </span>were<span style='letter-spacing:-.1pt'>
  </span>erythema<span style='letter-spacing:-.05pt'> </span>in<span
  style='letter-spacing:-.1pt'> </span>7<span style='letter-spacing:-.1pt'> </span>(87.5%)<span
  style='letter-spacing:-.05pt'> </span>subjects,<span style='letter-spacing:
  -.05pt'> </span>swelling<span style='letter-spacing:-.1pt'> </span>in<span
  style='letter-spacing:-.1pt'> </span>7<span style='letter-spacing:-.1pt'> </span>(87.5%)<span
  style='letter-spacing:-.05pt'> </span>subjects,<span style='letter-spacing:
  -.1pt'> </span>and<span style='letter-spacing:-.05pt'> </span>warm<span
  style='letter-spacing:-.15pt'> </span>sensation<span style='letter-spacing:
  -.05pt'> </span>in<span style='letter-spacing:-.1pt'> </span>4<span
  style='letter-spacing:-.1pt'> </span>(50.0%)<span style='letter-spacing:-.1pt'>
  </span>subjects.</span></p>
  <p class=TableParagraph style='margin-top:0in;margin-right:11.9pt;margin-bottom:
  0in;margin-left:5.35pt;margin-bottom:.0001pt;text-align:justify'><span
  style='font-size:10.0pt'>Almost all injection site reactions had resolved by
  8 hours postdose. Injection site reactions were mild or moderate<span
  style='letter-spacing:-2.35pt'> </span>in intensity. One (12.5%) subject
  experienced a severe injection site reaction (erythema) which resolved by 2
  hours<span style='letter-spacing:-2.35pt'> </span>post-treatment.</span></p>
  <p class=TableParagraph style='margin-right:12.2pt'><span style='font-size:
  10.0pt'>There were no deaths, no serious adverse reactions (SAEs), and no
  discontinuations due to a TEAE in this study.<span style='letter-spacing:
  .05pt'> </span>None of the TEAEs suggested a deterioration of cardiac
  function. No clinically meaningful changes were observed<span
  style='letter-spacing:-2.35pt'> </span>in<span style='letter-spacing:-.05pt'>
  </span>clinical laboratory<span style='letter-spacing:-.1pt'> </span>values,<span
  style='letter-spacing:-.1pt'> </span>vital signs,<span style='letter-spacing:
  -.15pt'> </span>or<span style='letter-spacing:-.1pt'> </span>ECGs.</span></p>
  <p class=TableParagraph style='margin-top:6.1pt'><b><u><span
  style='font-size:10.0pt'>Other<span style='letter-spacing:-.1pt'> </span>Observations<span
  style='letter-spacing:-.1pt'> </span>Related<span style='letter-spacing:-.05pt'>
  </span>to<span style='letter-spacing:-.05pt'> </span>Safety</span></u></b></p>
  <p class=TableParagraph style='margin-top:5.9pt;margin-right:8.55pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><u><span
  style='font-size:10.0pt'>Self-administration of Study Drug:</span></u><span
  style='font-size:10.0pt'> The administration method groups were similar with
  respect to the summary of<span style='letter-spacing:.05pt'> </span>all
  TEAEs. With regards to injection site reactions, the administration methods
  were generally similar (2 of 3<span style='letter-spacing:.05pt'> </span>subjects
  who self-administered icatibant; 5 of 5 subjects who had icatibant
  administered by an HCP). Erythema was<span style='letter-spacing:-2.35pt'> </span>the
  only severe injection site reaction that was present in 1 subject who had
  icatibant administered by an HCP. The<span style='letter-spacing:.05pt'> </span>administration<span
  style='letter-spacing:-.1pt'> </span>method<span style='letter-spacing:-.1pt'>
  </span>groups<span style='letter-spacing:-.05pt'> </span>were<span
  style='letter-spacing:-.1pt'> </span>generally<span style='letter-spacing:
  -.05pt'> </span>similar<span style='letter-spacing:-.05pt'> </span>with<span
  style='letter-spacing:-.05pt'> </span>respect<span style='letter-spacing:
  -.05pt'> </span>to<span style='letter-spacing:-.1pt'> </span>all<span
  style='letter-spacing:-.05pt'> </span>other<span style='letter-spacing:-.1pt'>
  </span>safety<span style='letter-spacing:-.1pt'> </span>endpoints.</span></p>
  </td>
 </tr>
 <tr style='height:226.0pt'>
  <td width=639 colspan=3 valign=top style='width:478.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:226.0pt'>
  <p class=TableParagraph style='margin-top:3.0pt'><b><u><span
  style='font-size:10.0pt'>Conclusions</span></u></b></p>
  <p class=TableParagraph style='margin-top:5.85pt;margin-right:5.5pt;
  margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt'><span
  style='font-size:10.0pt'>Icatibant is an efficacious treatment for acute
  attacks of HAE including cutaneous, abdominal, and laryngeal attacks,<span
  style='letter-spacing:-2.35pt'> </span>as demonstrated by the reproducibility
  and consistency of efficacy across multiple endpoints, in the open-label
  study<span style='letter-spacing:-2.35pt'> </span>of icatibant in adult
  Japanese subjects. Icatibant provided rapid resolution of symptoms.
  Clinically meaningful<span style='letter-spacing:.05pt'> </span>efficacy<span
  style='letter-spacing:-.05pt'> </span>in the<span style='letter-spacing:-.05pt'>
  </span>primary and all<span style='letter-spacing:-.1pt'> </span>secondary
  endpoints<span style='letter-spacing:-.05pt'> </span>was<span
  style='letter-spacing:-.1pt'> </span>demonstrated.</span></p>
  <p class=TableParagraph style='margin-right:19.65pt'><span style='font-size:
  10.0pt'>Systemic exposure to icatibant in Japanese subjects was demonstrated
  and was found to induce sufficient clinical<span style='letter-spacing:-2.35pt'>
  </span>response.</span></p>
  <p class=TableParagraph style='margin-right:26.4pt;text-align:justify'><span
  style='font-size:10.0pt'>Icatibant was generally well tolerated, and no new
  safety signals were identified in adult Japanese subjects with<span
  style='letter-spacing:-2.35pt'> </span>HAE. The safety profile of icatibant
  in adult Japanese subjects with HAE was favorable and consistent with the<span
  style='letter-spacing:-2.35pt'> </span>disease<span style='letter-spacing:
  -.05pt'> </span>and<span style='letter-spacing:-.05pt'> </span>with<span
  style='letter-spacing:.05pt'> </span>icatibant<span style='letter-spacing:
  -.05pt'> </span>safety<span style='letter-spacing:-.05pt'> </span>profile<span
  style='letter-spacing:-.05pt'> </span>in<span style='letter-spacing:-.05pt'> </span>adult<span
  style='letter-spacing:-.05pt'> </span>non-Japanese subjects<span
  style='letter-spacing:-.15pt'> </span>with<span style='letter-spacing:-.1pt'>
  </span>HAE.</span></p>
  <p class=TableParagraph style='margin-right:9.4pt'><span style='font-size:
  10.0pt'>The efficacy and safety endpoints were generally similar in subjects
  who self-administered icatibant compared with<span style='letter-spacing:
  -2.35pt'> </span>subjects<span style='letter-spacing:-.1pt'> </span>who had
  icatibant<span style='letter-spacing:-.05pt'> </span>administered<span
  style='letter-spacing:-.05pt'> </span>by<span style='letter-spacing:-.05pt'> </span>an<span
  style='letter-spacing:-.05pt'> </span>HCP.</span></p>
  <p class=TableParagraph style='margin-right:15.5pt'><span style='font-size:
  10.0pt'>The treatment response to icatibant in adult Japanese subjects
  experiencing an acute attack of HAE was consistent<span style='letter-spacing:
  -2.35pt'> </span>with the treatment<span style='letter-spacing:-.05pt'> </span>response<span
  style='letter-spacing:-.05pt'> </span>in adult non-Japanese<span
  style='letter-spacing:-.05pt'> </span>subjects.</span></p>
  <p class=TableParagraph style='margin-right:23.6pt;text-align:justify'><span
  style='font-size:10.0pt'>In conclusion, this study demonstrated that
  icatibant can address the unmet medical need for a safe and effective<span
  style='letter-spacing:-2.35pt'> </span>treatment<span style='letter-spacing:
  -.05pt'> </span>for acute attacks<span style='letter-spacing:-.05pt'> </span>of<span
  style='letter-spacing:-.05pt'> </span>HAE<span style='letter-spacing:-.05pt'>
  </span>in adult Japanese subjects.</span></p>
  </td>
 </tr>
 <tr style='height:17.5pt'>
  <td width=639 colspan=3 valign=top style='width:478.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:17.5pt'>
  <p class=TableParagraph style='margin-top:2.8pt'><span style='font-size:10.0pt'>Date<span
  style='letter-spacing:-.05pt'> </span>of<span style='letter-spacing:-.1pt'> </span>report:<span
  style='letter-spacing:-.05pt'> </span>14<span style='letter-spacing:-.1pt'> </span>Jul<span
  style='letter-spacing:-.15pt'> </span>2016</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

</div>

</body>

</html>
